University of South Florida

Digital Commons @ University of South Florida
USF Tampa Graduate Theses and Dissertations

USF Graduate Theses and Dissertations

January 2022

Determining the Role of Dendritic Cells During Response to
Treatment with Paclitaxel/Anti-TIM-3
Alycia Gardner
University of South Florida

Follow this and additional works at: https://digitalcommons.usf.edu/etd
Part of the Cell Biology Commons, Immunology and Infectious Disease Commons, and the Oncology
Commons

Scholar Commons Citation
Gardner, Alycia, "Determining the Role of Dendritic Cells During Response to Treatment with Paclitaxel/
Anti-TIM-3" (2022). USF Tampa Graduate Theses and Dissertations.
https://digitalcommons.usf.edu/etd/9358

This Dissertation is brought to you for free and open access by the USF Graduate Theses and Dissertations at
Digital Commons @ University of South Florida. It has been accepted for inclusion in USF Tampa Graduate Theses
and Dissertations by an authorized administrator of Digital Commons @ University of South Florida. For more
information, please contact scholarcommons@usf.edu.

Determining the Role of Dendritic Cells During Response to Treatment with Paclitaxel/AntiTIM-3

by

Alycia Gardner

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
Department of Cell Biology, Microbiology and Molecular Biology
College of Arts and Sciences
University of South Florida

Major Professor: Brian Ruffell, Ph.D.
Amer Beg, Ph.D.
Jose R. Conejo-Garcia, M.D., Ph.D.
Conor Lynch, Ph.D
Hatem Soliman, M.D.

Date of Approval:
January 27th, 2022

Keywords: immunotherapy, CD8+ T cells, tumor immunology
Copyright © 2022, Alycia Gardner

Acknowledgments
First, I would like to express my gratitude to my mentor, Dr. Brian Ruffell. His guidance,
assistance, and encouragement over the course of my PhD have been invaluable. I am also
grateful to the members of my thesis committee: Dr. Jose R. Conejo-Garcia, Dr. Amer Beg, Dr.
Conor Lynch, and Dr. Hatem Soliman. Their feedback and thoughtful suggestions have
contributed greatly to this work, and to my growth as a scientist. Further, I would like to thank
Dr. David DeNardo for his time and expertise serving as the external chair of my committee. I
would also like to express my gratitude to Dr. Katarzyna Rejniak, with whom we collaborated to
perform the mathematical analysis in Chapter 3 of this work. Her patience and expertise are
immensely appreciated.
I would also like to thank the current and former members of the Ruffell lab for their
technical assistance, troubleshooting help, and support over the years. In particular for their
contributions to this work, I would like to thank Dr. Kay Hänggi, Dr. Álvaro de Mingo Pulido,
Alexis Onimus, and Sarah Bazargan.
The Moffitt Core Facilities have also been instrumental in the completion of these
studies. I would particularly like to thank Joe Johnson and Aga Kasparzak from the Analytic
Microscopy Core for their advice and technical assistance over the years. I also thank the
Cancer Biology PhD program, especially our director, Dr. Ken Wright, and the administrators
with whom I worked closely: Cathy Gaffney, Janet Opel, and Tiffany Ferrer.

Table of Contents
List of Figures ............................................................................................................................ iii
Abstract....................................................................................................................................... v
Chapter 1: Introduction................................................................................................................ 1
Dendritic Cell Biology ...................................................................................................... 1
Dendritic Cell Development and Identification ...................................................... 1
Dendritic Cell Maturation ...................................................................................... 6
Solid Tumor Immunology ................................................................................................. 7
Dendritic Cell-Based Therapies ..................................................................................... 15
In Vivo Activation ............................................................................................... 15
Blocking Inhibitory Signals ................................................................................. 19
In Vivo Expansion .............................................................................................. 20
Dendritic Cell Vaccines ...................................................................................... 21
Peptide/Protein Vaccines ................................................................................... 24
Discussion ..................................................................................................................... 25

Chapter 2: TIM-3 Suppresses Both CXCL9 Expression by Dendritic Cells and Response
to Chemotherapy................................................................................................................. 27
Introduction ................................................................................................................... 27
Materials and Methods .................................................................................................. 28
Animal Studies ................................................................................................... 28
Generation of Bone Marrow-Derived DCs (BMDCS) .......................................... 29
Immunohistochemistry (IHC) .............................................................................. 30
Immunofluorescence (IF) ................................................................................... 32
Flow Cytometry .................................................................................................. 32
Quantitation and Statistical Analysis .................................................................. 33
Results .......................................................................................................................... 34
TIM-3 Blockade Promotes Chemokine Expression by Tumor cDCs ................... 34
CXCL9 Expression by cDC1 is Required for Response to αTIM-3/PTX ............. 36
Lymph Node Egress is not Required for Response to TIM-3 Blockade .............. 39
TIM-3 Expression in Breast Tumors ................................................................... 43
Discussion ..................................................................................................................... 45
Chapter 3: TIM-3 blockade promotes intratumoral dendritic cell and T cell interactions in
an IL-12 dependent manner ................................................................................................ 49
Introduction ................................................................................................................... 49
Materials and Methods .................................................................................................. 50
Animal Studies ................................................................................................... 50
Generation of Bone Marrow-Derived DCs (BMDCS) .......................................... 51
Immunofluorescence (IF) ................................................................................... 52
Image Analysis .................................................................................................. 53
Flow Cytometry .................................................................................................. 54
Statistical Analysis ............................................................................................. 55
i

Results .......................................................................................................................... 55
CXCR3 Regulates T Cell Effector Function but not Recruitment During
Response to αTIM-3/PTX ............................................................................. 55
Intratumoral Injection of BMDCs Reduces Tumor Growth .................................. 58
αTIM-3 Promotes Co-Localization of cDC1s and CD8+ T Cells in a Cxcl9Dependent Manner ...................................................................................... 59
cDC1 production of IL-12 is critical for response to αTIM-3/PTX ........................ 63
Dual expression of CXCL9 and IL12B is rare within human tumors ................... 65
Discussion ..................................................................................................................... 66
Chapter 4: Results, Clinical Implications, and Future Work ....................................................... 69
Summary of Results ...................................................................................................... 69
The Role of Intratumoral Localization in Anti-Tumor Responses.................................... 71
Integration of Tim-3 Blockade into Other Therapeutic Modalities ................................... 75
Future Directions ........................................................................................................... 76
References Cited ...................................................................................................................... 78
Appendix A: Institutional Animal Care and Use Committee Approvals ...................................... 95
Appendix B: Copyright Permissions of Previously Published Material ..................................... 104

ii

List of Figures
Figure 1.1

Dendritic cell (DC) differentiation.......................................................................... 2

Figure 1.2

Factors regulating cDC1 function in the tumor microenvironment ...................... 11

Figure 1.3

Treatment modalities targeting DCs ................................................................... 16

Figure 1.4

Process of generating whole cell DC vaccines ................................................... 23

Figure 2.1

CXCL9 is produced by dendritic cells in human breast tumors ........................... 35

Figure 2.2

CXCR3 signaling is required for response to αTIM-3/PTX.................................. 36

Figure 2.3

CXCL9 expression drives response to TIM-3 blockade ...................................... 37

Figure 2.4

TIM-3 expression within MMTV-PyMT mammary tumors ................................... 38

Figure 2.5

Characterization of immune infiltrate in orthotopically implanted MMTVPyMT tumors ..................................................................................................... 38

Figure 2.6

cDC1 specific CXCL9 production drives response to αTIM-3/PTX ..................... 39

Figure 2.7

TIM-3 blockade does not promote antigen presentation in the draining
lymph nodes ...................................................................................................... 41

Figure 2.8

Treatment with FTY720 does not prevent response to αTIM-3/PTX ................... 42

Figure 2.9

Immunohistochemistry staining to examine TIM-3 expression in human
tumor samples ................................................................................................... 43

Figure 2.10

Immunofluorescence staining to examine TIM-3 expression in human
breast tumors ..................................................................................................... 44

Figure 3.1

The CXCR3 axis does not promote T cell infiltration during TIM-3
blockade ............................................................................................................ 56

Figure 3.2

CXCR3 drives T cell effector function during TIM-3 blockade ............................ 57

Figure 3.3

Intratumoral injection of bone marrow dendritic cells controls tumor
growth ................................................................................................................ 58

Figure 3.4

TIM-3 blockade promotes colocalization of cDC1 and CD8+ T cells .................. 60

Figure 3.5

Additional data regarding the localization of CD8+ T cells in αTIM-3/PTX
treated tumors.................................................................................................... 62
iii

Figure 3.6

cDC1 production of IL12 is required for response to αTIM-3/PTX ...................... 64

Figure 3.7

Expression of CXCL9 and IL12B within human tumor cDCs .............................. 65

Figure 4.1

Graphical representation of findings ................................................................... 70

iv

Abstract
Intratumoral CD103+ dendritic cells (cDC1) are required for anti-tumor immune responses.
In tumors that are poorly responsive to immunotherapeutic approaches targeting T cells, targeting
cDC1 represents an alternative approach that may be useful in improving patient response rates.
As such, it is critical to understand cDC1 function within tumors, and what may be preventing
optimal function of cDC1. TIM-3 is a receptor that is highly expressed by cDC1 in murine and
human mammary tumors, and TIM-3 blocking antibodies are currently being evaluated in clinical
trials for a number of solid and hematological malignancies. In order to best design combinatorial
therapeutic approaches, it is important to understand the mechanism by which therapies act. This
project aims to understand the mechanism by which combination therapy with paclitaxel (PTX)
and TIM-3 blockade reduces the rate of mammary tumor growth.
In order to do so, we identify Cxcl9, Cxcl10, Cxcl11, and Il12b as being upregulated by
cDC1 following PTX/TIM-3 blockade. By blocking signaling through CXCR3 (the receptor for
CXCL9, CXCL10, and CXCL11) we determine that signaling through the CXCR3 axis was
responsible for the observed reduction in the rate of tumor growth. We next evaluate whether the
chemokines themselves are necessary for therapeutic response, using mixed bone marrow
chimeras and diphtheria toxin depletion. In doing so, we identify CXCL9 production by cDC1 as
a requirement for the observed reduction in tumor growth. As one role for CXCL9 has been shown
to be mediating lymph node migration by CD8+ T cells, we then inhibit lymph node egress and
use a fluorescently labelled tumor model to assess involvement of the lymph node following
initiation of anti-tumor immunity. We did not observe changes in antigen presentation by cDC1 in
the lymph node, or alterations in responsiveness to PTX/TIM-3 blockade when lymph node egress
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was inhibited. Together, these data point suggest that cDC1 may be interacting with CD8+ T cells
within the tumor, and that these interactions may be supporting CD8+ T cell functionality.
To evaluate this, we first use flow cytometry to assess T cell production of IFNγ, as a
measure of the effector function. We find that treatment with PTX/TIM-3 blockade increases IFNγ
production by CD8+ T cells, and that this is increase is prevented when signaling through CXCR3
is blocked. We next assess the distance between CD8+ T cells and their nearest cDC1 in tumors
treated with PTX/TIM-3 blockade as compared to a PTX/IgG2a control. We find that CD8+ T cells
are located closer to cDC1 in tumors treated with PTX/TIM-3 blockade, without increases in either
CD8+ T cell or cDC1 infiltration. We then use mixed bone marrow chimeras and diphtheria toxin
depletion to evaluate the role of two main functions of cDC1 within tumors: antigen crosspresentation on MHCI and production of IL-12. We find that IL-12 production by cDC1 is required
for response to PTX/TIM-3 blockade, while antigen presentation by MHCI is dispensable. Taken
together, the data described herein suggests that treatment with TIM-3 blockade drives increased
CXCL9 production by cDC1, bringing CD8+ T cells into closer proximity and increasing their
exposure to IL-12, thereby supporting CD8+ T cell functionality.
Overall, these studies propose a mechanism by which TIM-3 blockade functions in
mammary tumors and provide direct evidence for the ability of cDC1 to support CD8+ T cells within
the tumor. Understanding these aspects has implications for the design of therapeutic strategies
using antibodies against TIM-3.
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Chapter 1: Introduction1
Dendritic Cell Biology
The role of dendritic cells (DCs) in the adaptive immune response was first described by
Ralph Steinman and Zanvil A. Cohn in 1973 (1). Since then, several different dendritic cell subsets
have been described, based on differing expression of surface markers, functionality, or pathways
of development (figure 1.1). Dendritic cells function within the adaptive immune response as
professional antigen presenting cells, meaning that they are responsible for presenting antigen to
lymphocytes, such as T cells. There are, however, multiple dendritic cell subsets, each with their
own unique functionality. In many cases, this functionality is still being elucidated. Indeed, as
technology improves and our ability to differentiate between different cell subtypes increases, new
DC subsets are still being identified. Of note, however, is the fact that there is a high degree of
agreement, at both the genetic and functional level, between dendritic cells in mice and humans
(2, 3), indicating that mouse models will continue to be a useful tool for understanding the
landscape of human dendritic cell subsets. Outlined herein is an overview of the different DC
subsets and their functionality, both at homeostasis and in the context of immune responses.
Dendritic Cell Development and Identification
Dendritic cells are central regulators of the adaptive immune response. The traditional
function of dendritic cells is to transport antigen to draining lymph nodes and cross-present
antigen to cytotoxic T lymphocytes. A subset of dendritic cells [termed the conventional/classical
dendritic cells (cDCs)] are critical for fulfilling this role (4, 5). As part of the hematopoietic cell
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A note to the reader: Portions of this chapter have been previously published in review articles
in the journals Trends in Immunology, Gardner and Ruffell 2016 (4) and Frontiers in
Immunology, Gardner et al. 2020 (5).
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Figure 1.1: Dendritic cell (DC) differentiation. DCs are part of the hematopoietic cell lineage,
originating from hematopoietic stem cells, which subsequently differentiate into common myeloid
progenitors (CMPs). The transcription factor Nur77 drives the differentiation of CMPs through
several steps into monocytes, which can further differentiate into monocyte DCs (moDCs) under
inflammatory conditions. In the absence of Nur77, CMP will differentiate through multiple stages
into a common dendritic cell progenitor (CDP). The conventional type 1 DC (cDC1), conventional
type 2 DC (cDC2), and plasmacytoid DC (pDC) subsets arise from the CDP, with the critical
transcription factors shown for each lineage. Markers for each DC subset are shown on the right
for mouse (black) or human (green). cDC1 in mice can be identified by expression of either CD8α
in the lymphoid organs or CD103 within peripheral tissues. TLR, Toll-like receptor.

lineage, all true DC subsets originate from hematopoietic stem cells, which subsequently
differentiate into common myeloid progenitors (CMPs). The transcription factor Nur77 drives CMP
differentiation through several steps into monocytes, which can further differentiate into monocyte
DCs (moDCs) under inflammatory conditions. moDCs can be identified in both mice and humans
by expression of CD14, the Fc receptors FcγRI and FcεRI, CD172a (also known as SIRPα), and
CD206. In mice, these cells also express CD11b, and in humans the cells also express CD1a or
CD1c. As these last markers (CD11b, CD1c in mice and humans, respectively) are also coexpressed with another DC subset (the type 2 conventional dendritic cells (cDC2s)), identification
of moDCs as a unique subset has been complicated. Indeed, a meta-analysis of several

2

scRNAseq studies suggest that moDCs and cDC2 may exist as a continuum, rather than discrete
subsets (2). However, recent studies have shown that the Fc receptors can be used to
successfully distinguish moDCs from other DC or macrophage subsets (6, 7). moDCs also
express higher levels of CLEC10A and CD127 than cDC2 (8). In particular, CD127 may be useful
when distinguishing peripheral cDC2 and moDCs, as nearly half of unstimulated moDCs were
shown to express it, as compared with <5% of cDC2 (8). Monocyte DCs are capable of trafficking
antigen to the lymph nodes and presenting it to T cells, but their capacity to do so is a fraction of
that observed in the cDCs (9, 10). However, moDC infiltration into the site of local immune
responses is enhanced during infections and other inflammatory conditions (11, 12). In these
contexts, moDCs have also been called ‘TipDCs’ for their capacity for tumor necrosis factor α
(TNFα) and inducible nitric oxide synthase (INOS) production (12). Specific production of these
cytokines suggests that in inflammatory contexts moDCs are likely to play a role in regulating T
cell responses.
Monocytes also give rise to another subset of cells traditionally thought of as dendritic
cells, the Langerhans cell (13, 14). The characterization of Langerhans cells as dendritic cells
was initially based on their phenotype (Langerhans cells exhibit dendrite-like arms, as do other
DC subsets), their ability to migrate to the lymph node to present antigen (15), and their ability to
activate T cells (16, 17). Langerhans cells are identifiable from other DC subsets by their
expression of the C-type lectin receptor langerin (although this is sometimes shared with type 1
conventional dendritic cells), as well as the fact that they specifically reside in the epidermis (18).
In addition to Langerhans cells, another DC subset known as dermal DCs resides in the
epidermis, but these two subsets can be functionally distinguished by increased radioresistance
by the Langerhans cells (7). The dermal DCs residing in the epidermis represent a mix of cDC1
and cDC2, deriving from bone marrow precursors (19-21). Expression of the marker CD24 is key
for distinguishing between Langerhans cells and cDC2 when cell subsets are being characterized
by flow cytometry (7). Although the Langerhans cell has classically been termed a dendritic cell
3

based on both morphology and functionality, recent work has shown that Langerhans cells
express several markers that are shared with macrophages (18). Langerhans cells are also
primarily derived from embryonic fetal liver monocytes (22), and certain macrophage subsets also
derive from these precursors (23, 24). On the basis of these points, and on the increasing
movement to classify immune cells based on ontogeny rather than phenotype and/or function, it
is currently suggested that Langerhans cells are more correctly classified as macrophages rather
than dendritic cells (23).
Similar to Langerhans cells, follicular dendritic cells are so named for their stellate
phenotype and predominant localization at the margin of germinal centers in secondary lymphoid
follicles (25), but are not true dendritic cells. Follicular DCs develop from perivascular precursors
that originate from stromal cells located throughout the body (26, 27). However, follicular DCs are
able to present antigen on their surface. Presentation of antigen to B cells by follicular DCs in the
germinal center is key for the formation of memory B cell populations (26, 28). Although follicular
DCs can clearly play a key role in the induction of adaptive immune responses, and can present
antigen, they are not true DCs and we mention them here only for the sake of clarity.
In the absence of Nur77 expression, the CMP will differentiate through several steps to
another precursor cell known as the common dendritic cell progenitor (CDP) (4). This precursor
gives rise to the remainder of the currently established dendritic cell subsets. The two major
subsets of dendritic cells that originate from CDP are the cDCs and plasmacytoid dendritic cells
(pDCs). While cDCs, as their name suggests, exhibit the expected, conventional function of
antigen presentation, plasmacytoid DCs tend to have minimal antigen presentation ability.
Instead, pDCs produce significant amounts of type I interferon, as well as other inflammatory
cytokines including TNFα and IL-6, in response to single-stranded nucleic acids (4, 29, 30).
Production of these cytokines following recognition of single-stranded RNA and DNA supports
the key role pDCs play during immune responses against infections by viruses and other
pathogens (31). Plasmacytoid DCs are prevalent in the blood and spleen but are found in smaller
4

numbers in peripheral tissues. They can be identified in mice by expression of the markers B220,
Ly6C, and PDCA-1, and in humans by CD123, BDCA2/CD303, and BDCA4/CD304. In both
species, pDCs selectively express TLR7 and TLR9, again highlighting their key role in responding
to single-stranded RNA and DNA. Interestingly, pDCs have recently been segregated into two
lineages, based on the precursors from which they differentiate (32). While those that differentiate
from the CDP have been found to process and display antigen, a phenotypically similar but
functionally distinct subset that derives from IL-7R+ lymphoid progenitors is incapable of antigen
presentation (33). The phenotypic similarity of these two types of pDC is likely to have contributed
to some level of confusion over the role of pDCs in immunity, and care should be taken to
distinguish between the two types.
The cDC subsets are the other DC subsets that differentiate from the CDP. As the name
suggests, cDCs are the quintessential dendritic cell, capable of presenting antigen and inducing
strong T cell responses. There are two distinct lineages of cDCs with unique phenotypes and
functional roles. The cDC1 subset expresses several markers in common between mice and
humans, including XCR1, CLEC9a, CADM1, BTLA, and CD26 (34). Human cDC1 additionally
express CD141 (BDCA3). In mice, cDC1 additionally express CD8α (in the lymphoid resident
cDC1 population) or CD103 (in the migratory population) (4). The latter set of markers (CD141,
CD8α/CD103) were used during initial identification of the subset, and as such are the markers
most commonly used to delineate this population (35-37). Differentiation of cDC1 from the CDP
is governed by expression of the transcription factors BATF3 and IRF8. In contrast, cDC2
differentiation is governed by expression of IRF4. cDC2 are most easily identified by the absence
of cDC1 markers, but in humans the cells can also be identified by higher expression of CD11b,
SIRP1α, and CD1c, and in mice by higher expression of CD11b and SIRP1α. It should be noted
that LAMP3+ cDC have also recently been defined as an activated population of cDCs that derives
from either the cDC1 or cDC2 population, and has alternatively been named at cDC3 and ‘mature
DCs enriched in regulatory molecules’ (mregDCs) (38-40). The extent to which the LAMP3+ cDCs
5

derive from either of these subsets depends upon the tissue being examined, but the ability of the
cDC1-derived LAMP3+ population to express IL-12 and other genetic programs indicate that the
cells retain much of their lineage-defining properties.
Beyond these relatively well-established DC subsets, the DC3 subset appears to be an
emerging class of DC that does not develop from either monocytes (as with the moDCs) or from
the CDP (as is the case for the cDC subsets). These cells were first identified using scRNAseq
data and described as a subset of either moDCs, based on their expression of CD14 (41, 42), or
cDC2s, based on expression of CD1C (43). However, recent studies show that DC3 are
developmentally and ontogenically distinct from both cDCs and moDCs (44, 45). DC3 expression
of CD163 can be used to identify them as a separate subset from both cDC2 and moDCs (4145). A lack of CD88 expression by the DC3 subset can further be used to distinguish them from
monocytes (thus defining DC3s as CD88 -CD1c+CD2+CD163+, with or without expression of
CD14) (44, 45). DC3s are also shown to develop from a precursor upstream of the CMP, instead
developing from the granulocyte macrophage progenitor (GMP) (44, 45). scRNAseq analysis
reveals that low IRF8 expression by the GMP gives rise to DC3, while IRF8hi GMP give rise to the
cDC and pDC subsets (45). GM-CSF is also required for development of the DC3 subset (44).
Interestingly, despite their disparate developmental pathways, DC3 were capable of priming T
resident memory (Trm) cells in vitro and were found to correlate with the presence of Trm cells in
human breast cancer (44), suggesting that they can play a functional role in the induction of
adaptive immune responses.
Dendritic Cell Maturation
Expansion of DC progenitors occurs in the bone marrow, with the different progenitor cells
developing based on the available signals (e.g. FMS-related tyrosine kinase 3 ligand (Flt3L)
driving expansion of cDC progenitors (46). In the case of cDCs, the progenitors then differentiate
further into immature cDC within tissues (47). The immature cDCs are capable of acquiring
antigen but are unable to stimulate T cells (48-50). It is possible that the presence of immature
6

DCs within tumors has contributed to some extent to findings that intratumoral DCs play a
tolerogenic and/or immunosuppressive role (4). Maturation is marked by the movement of
MHC/peptide complexes to the cell membrane, upregulation of the costimulatory molecules
CD80/CD86, and expression of cytokines that drive T-cell proliferation and differentiation [e.g.,
interleukin-12 (IL-12)]. These molecules are referred to as signals 1, 2, and 3, respectively, and
are required for proper T-cell activation (51). DC activation is normally considered to result from
detection of damage- or pathogen-associated molecular patterns (DAMPs or PAMPs,
respectively) by pattern recognition receptors such as the TLRs. Within tumors many of these
same receptors recognize endogenous, constitutively expressed damage-associated molecular
patterns that are released or expressed on the surface of dead or dying cells (52). In contrast to
apoptotic cells, dead immunogenic cells induce expression of MHCII, CD40, CD80, and CD86 on
DCs, along with the release of the inflammatory cytokines IL-1β, IL-6, IL-12, and tumor necrosis
factor-α (53).
Solid Tumor Immunology
The basis for our current understanding of anti-tumor immunity as it relates to dendritic
cell involvement is laid out in a seminal review by Chen and Mellman (54). As tumor cells die,
they release antigens. These antigens are taken up by dendritic cells or other antigen presenting
cells (APCs), which then traffic the antigen back to the lymph node. Via recognition of the antigens
presented by APCs on the Major Histocompatibility Complex (MHC) class I or II, CD8 + or CD4+ T
cells, respectively, in the lymph node are educated and activated. These T cells, which express
T cell receptors (TCRs) specific for the tumor antigens presented, can then traffic back to the site
of the tumor. At the tumor site, the T cells can recognize antigens presented on the tumor cells.
Engagement of the TCR with the MHC-antigen complex leads to a downstream signaling cascade
within the T cell, leading to the release of perforins and granzyme, which function to kill the tumor
cells via induction of pores in the cell membrane. When combined with certain stimulatory signals,
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TCR engagement can also induce cytokine expression by the T cells, which can support further
T cell activation and function (55, 56).
As ‘professional antigen presenting cells’, DCs in general, and the cDC population in
particular, are the key APC subset responsible for education of T cells. Lymphoid-resident cDCs
exist in the spleen and lymph nodes and are critical for sampling blood- and lymph-borne antigen,
respectively. More relevant for solid tumor immune responses are the non-lymphoid, migratory
tissue cDCs that can directly transport antigen from its tissue of origin to peripheral sites (18, 57).
Recent data has shown that migratory cDCs can additionally pass tumor antigen to resident cDCs
to allow the resident cDCs to present antigen to T cells within the lymph node (58). Antigen
presentation by the resident or migratory cDC subset leads to differential priming of CD8 + T cells,
with CD103+ migratory cDC1 interactions priming CD8+ T cells required for optimal anti-tumor
efficacy (58).
Initial evidence of the key role of cDC1 during anti-tumor immunity was gathered through
work using Batf-/- mice (59), which lack the cDC1 subset, as they do not express the key
transcription factor, Batf3, that drives this subset’s development. While wild-type mice are able to
mount a strong immune response against immunogenic tumor models, Batf3-/- mice failed to reject
the tumors, instead showing a similar pattern of tumor growth as Rag2-/- mice, which lack mature
B and T cells (59, 60). The lack of response from Batf3-/- mice demonstrates that cDC1 are as
critical to the induction of adaptive anti-tumor immune responses as are T cells, the immune
subset that is largely recognized as being responsible for tumor killing. This work has since been
supplemented by additional experiments making use of Batf3-/- mice, including work showing that
cDC1 are required during response to blockade of the programmed death-1 (PD-1) axis (61, 62).
The ability of cDC1 to induce anti-tumor immune responses has been traced back to their ability
to transport antigen from tumors into draining lymph nodes. In line with this, migratory cDC1 are
both the only APC subset capable of causing robust activation and proliferation of CD8 + T cells
ex vivo, and the only cDC subset capable of transporting antigen to the lymph node in two studies
8

using melanoma models (61, 63). cDC1 trafficking to the lymph node in order to generate systemic
anti-tumor immune responses is governed by expression of CCR7 (63). Interestingly, CCR7 is
largely expressed by an activated subset of cDC1 that also express LAMP3+ (64). Mice lacking
CCR7-expressing cDC1 fail to recruit CD8 + T cells to the tumor, and T cells present in the tumor
microenvironment fail to proliferate, leading to an overall lack of immune control (63). The inability
of tumors to recruit cDC1 similarly prevents the development of an effective CD8 + T cell response
(65, 66). However, increasing the number of cDC1 within the tumor microenvironment can restore
response to immunotherapy (61, 65). Together, these studies highlight the importance of cDC1,
especially the migratory subset, both during baseline anti-tumor immunity, as well as during
therapeutic intervention with immune modulators.
In the non-tumor immune context, lymph-node resident cDCs are important for optimal
CD8+ T cell responses, following acquisition of antigen from migratory cDCs (67, 68). Antigen
transfer is also observed between migratory cDC1s and lymph node cDCs in a murine tumor
model, but whether this transfer is necessary for an anti-tumor immune response has not yet been
determined (63). That said, the ability of cDC1s to cross-present antigens is required for a
cytotoxic CD8+ T cell response, as loss of the cross-presentation in cDC1s prevents an immune
response from developing against highly immunogenic fibrosarcoma tumors (69). Crosspresentation by cDC1 is also enhanced by type I interferon (IFN) signaling (70), and the absence
of type I IFN in the tumor microenvironment or the inability of cDC1 to sense type I IFN are
sufficient to impair CD8+ T cell responsiveness (60, 70). Thus, cross-presentation of antigen to
naïve CD8+ T cells in the lymph node is a critical portion in the induction of successful anti-tumor
immune responses.
Another role for cDC1 that is becoming increasingly clear is the maintenance of CD8 + T
cell function within tumors. In secondary lymphoid organs and non-tumor models of immunity,
immune cell organization is critical to allow for effective signaling (71, 72). Of note, the localization
of CD8+ T cells near cDCs is critical for the induction of adaptive immune responses (73, 74). In
9

line with this, cDC1 production of cytokines has proven to be essential for responses to
immunotherapy. During response to adoptive cell therapy (ACT), cDCs capable of
CXCL9/CXCL10 production were needed in order to drive infiltration of transferred T cells into the
tumor (75). Production of CXCL9 and CXCL10, as well as expression of the cognate receptor
CXCR3 by CD8+ T cells has also recently been shown to be critical during therapeutic response
to anti-PD-1 therapy (76). The mechanism by which chemokine expression by cDCs promotes T
cell responses is unclear, but it may relate to the production of IL-12 by cDC1 within tumors (48,
77). In support of this, the feedback loop between cDC1 production of IL-12 and CD8+ T cell
production of IFN-γ is necessary for therapeutic efficacy of PD-L1 blockade (78). The requirement
for cDC1 signaling and crosstalk with CD8 + T cells during anti-tumor immune responses supports
the idea that targeting this interaction is a therapeutically viable option (figure 1.2). Indeed, a
recent study found that IL-4 blockade could reestablish IL-12 expression, thereby improving tumor
control via improved CD8+ T cell functionality (40). This is consistent with earlier studies
demonstrating that blocking the IL-10 receptor promotes T cell responses by increasing IL-12
expression by cDC1s.
Similarly, crosstalk between natural killer (NK) cells and cDC1 within tumors has recently
added a new dimension to the cDC1-CD8+ T cell axis in tumor immunology. Two groups
independently showed that NK cells produce either FMS-related tyrosine kinase 3 ligand (Flt3L)
or CCL5 and XCL1, thereby inducing cDC1 recruitment into the tumor microenvironment (66, 79).
Analyses of gene signatures in human tumors indicate that the presence of NK cells correlates
with the presence of cDC1 in this context as well, suggesting that manipulation of NK cell
presence within the tumor could indirectly improve the adaptive immune response (66, 79).
Signaling in the opposite direction has also been shown to be required, as cDC1 production of IL12 can lead to IFN-γ production by NK cells (80). Both neutralization of IL-12 and the absence of
cDC1 (through the use of Batf3-deficient mice) led to increased lung colonization following tail-
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Figure 1.2: Factors regulating cDC1 function in the tumor microenvironment. cDC1s interact
with several immune cell types through cytokine and chemokine signaling, including NK cells, T
cells, and macrophages. NK cells are critical for cDC1 recruitment and survival in the tumor through
production of Flt3L, CCL5, and XCL1. cDC1 have the capacity to cross-present exogenous antigen
to CD8+ T cells and stimulate naïve and previously activated T cells ex vivo; however, the importance
of antigen presentation by cDC1s in the tumor microenvironment is currently unclear. In contrast,
cDC1 production of IL-12, driven by IFN-γ or other inflammatory mediators, is necessary to sustain
a T cell response during chemotherapy or immune checkpoint blockade. cDC1 production of IL-12
can be directly inhibited by IL-10 released by macrophages or other immunosuppressive cells, as
well as tumor-derived factors that inhibit the maturation of cDC1s such as VEGF.

vein injection of multiple cell lines (80). The requirement for crosstalk between cDC1 and multiple
immune subsets is indicative of the complexity of immune responses within the tumor and
suggests that the localization of leukocytes within the tumor may be a critical regulator of their
function. Improvements in imaging techniques and analysis platforms will likely help dissect some
of this complexity.
Further evidence of the importance of cDC1 in the anti-tumor immune response is
provided by looking at the association of gene signatures to identify particular cell types and
patient prognoses or response rates. A cDC1 gene signature was found to be generally
associated with a positive prognosis in a study of human lung cancers (39). Similar findings have
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been made in hepatocellular carcinoma (38), and the presence of mature DCs in ovarian tumors
(81), along with the ratio of CD103 + cDC1 to CD103- DCs in breast cancer, head and neck
squamous cell carcinoma (HNSCC), and lung adenocarcinoma (48), have all been shown to
correlate with improved patient prognosis. Additionally, the presence of cDC1 within human
melanoma tumors correlated with improved response to anti-PD-1 therapy (66) as well as with
higher CD8+ T cell infiltration into tumors (82), which is associated with a positive prognosis across
multiple tumor types (83). Furthermore, genes specific for cDC1 correlate with the presence of
CXCL9 expression by human tumors in the TCGA database (75), further indicating that human
cDC1 are likely to produce similar chemokines and play a similar role in the tumor
microenvironment as mouse cDC1. As CXCL9 expression also correlates with response to antiPD-1 (76), there is likely to be a critical role for cDC1s in the context of patient responses to ICB.
While the aforementioned data suggest that cDC1 may be the only DC subset required
for the induction of anti-tumor immunity, this neglects the importance of CD4 + T cells, which play
a critical role in supporting CD8 + T cell activity (suggesting a role for cDC2 antigen presentation
to CD4+ T cells) (84-87). While cDC2 are dispensable for CD8 + T cell activation and proliferation
in some tumors (48, 63), this may be due to the specific models and therapies examined. For
example, cDC2s were found to be important during response to anthracycline chemotherapy (88),
and certain tumor models are responsive to adoptively transferred CD4 + T cells (89). cDC2 may
also be able to facilitate anti-tumor immune responses when cDC1 are absent, as in a Batf3-/model (90). There are also several reports describing recognition of tumor antigens by human
CD4+ T cells (89). As with cDC1, scRNAseq has shown that at the genetic level, mouse and
human cDC2 subsets in lung tumors show a high degree of overlap (39). This includes the
existence of functionally distinct subsets marked by expression of T-bet and RORγt (91).
Additionally, it was recently shown that following depletion of regulatory T cells (T reg), a subset of
cDC2 can effectively elicit intratumoral CD4 + T cell responses and subsequent tumor control in a
mouse model of melanoma (82). Upon Treg depletion, cDC2 were able to migrate to the draining
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lymph node and effectively induce differentiation of conventional CD4 + T cells (82). The observed
increase in tumor rejection specifically required CD4 + T cell priming in the lymph node, as FTY720
blockade of lymph node egress prevented the anti-tumor immune response (82).
Interestingly, when the cDC2 gene signature was correlated with prognosis for lung
adenocarcinoma patients, cDC2 were the DC subset most strongly associated with a positive
prognosis (39). Similarly, high levels of cDC2 in HNSCC and melanoma tumors, when combined
with low levels of regulatory T cells, correlated with longer progression free survival and higher
levels of CD4+ T cell infiltration, further suggesting a role for both cDC2 and CD4+ T cells in human
tumors (82). Given these data, it will be interesting to examine whether T reg are also preventing
cDC2 function in contexts other than melanoma. If so, depletion of the T reg subset may augment
the anti-tumor immune response in human tumors via increased cDC2 and CD4 + T cell activity.
This interplay further emphasizes the importance of a full understanding of interactions between
immune subsets in the tumor immune microenvironment, highlighting another potential indirect
method of improving anti-tumor immune responses.
In contrast to cDCs, whose role in anti-tumor immunity is associated with antigen
presentation, plasmacytoid DCs (pDCs) are usually associated with response to viral RNA and
DNA via production of high levels of type I IFN, along with other inflammatory cytokines, such as
IL6 and TNFα. However, pDCs do express MHCII and costimulatory molecules and could
therefore potentially act as antigen-presenting cells, although the antigen processing capabilities
of the cells are unclear (30, 32). As previously discussed, pDCs differentiate from both the myeloid
common dendritic cell progenitor (CDP) and IL-7R+ lymphoid progenitors (92). Only myeloidderived pDCs have been found to be able to process and display antigen (92). As such, the role
of pDCs in tumor regulation may depend on the extent to which they are myeloid derived, as well
as their activation state. At least one study has shown that tumor-associated pDCs are largely
inert, but that following intratumoral injection of a TLR7 ligand, pDCs can induce anti-tumor
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immune responses (33). Whether this response is directly attributable to antigen presentation by
myeloid-derived pDCs or is a result of type I IFN activation of cDC function is less clear.
In a similar vein, the role of pDCs in human tumors is less well-established than that of
the cDC subsets. As with cDC1 and cDC2, scRNAseq indicates that human pDCs mirror mouse
pDCs (39). The human pDC gene signature also correlates with a positive prognosis in lung
adenocarcinoma, although to a lesser degree than either cDC1 or cDC2 (39). In contrast, the
presence of pDC in breast tumors, as assessed by immunohistochemical staining, strongly
correlated with a poor overall prognosis (93). Additionally, pDCs found in the ascites of patients
with ovarian carcinoma induced IL-10 producing CD8+ regulatory T cells and inhibited T cell
proliferation (94). High-dimensional analysis has recently been employed by several groups to
identify heterogeneity within the classically defined pDC population in human samples (43, 95,
96), raising the possibility that the conflicting roles of pDCs in human tumors could be attributed
to the conflation of multiple subsets.
As mentioned previously, identification of monocyte derived DCs (moDCs) has been
complicated by the fact that they share major identification markers with macrophages and
CD11b+ cDC2 in mice. The recent identification of expression of the Fc receptors FcγRI and
FcεRI, however, has enabled researchers to specifically distinguish the subset (97). The minimal
ability of moDCs to transport antigens to the lymph nodes and activate T cells has raised
questions about their ability to induce de novo T cell responses (9, 10). However, it was recently
shown that for mice given adjuvant therapy with polyinosinic:polycytidilic acid (poly[I:C]), moDCs
were required for the anti-tumor response, whereas cDCs were dispensable (98). moDCs have
also been shown to enhance the survival of adoptively transferred T cells (12), and may further
regulate T cell activity within tumors through production of TNFα and nitric oxide, following
induction of TipDCs out of the moDC subset (30). Activation of p53 or inhibition of the BTK-IDOmTOR axis in myeloid precursors can even promote the formation of CD103 + moDCs with the
capacity to cross-present antigen and produce high amounts of IL-12 (99, 100). moDCs also
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appear to play a key role in the regulation of graft-vs.-leukemia (GVL responses following
therapeutic bone marrow transplants, with inhibition of XBP-1 splicing helping prevent graft-vs.host disease while maintaining a GVL response in both murine and human xenograft models
(101, 102). Thus, while the role of moDCs in the development of spontaneous anti-tumor immunity
is unclear, they appear critical in sustaining an immune response during certain inflammatory
conditions.
Dendritic Cell-Based Therapies
Immunotherapy continues to represent a promising avenue for new cancer therapies, especially
since many patients who respond exhibit durable responses. However, response rates for many
tumor types are still low, underscoring the need for continued improvement in our understanding
of anti-tumor immunity and approaches to enhance it. As expanded upon earlier, cDCs are central
inducers of the immune response, and targeting them may provide a method of improving immune
responses in cases where targeting T cells alone is ineffective. As DCs, especially cDC1, tend to
correlate with a positive prognosis when they are present in tumors, therapies targeting DCs focus
on enhancing DC function, increasing their numbers, or bypassing the tumor microenvironment
to promote systemic de novo anti-tumor immunity (figure 1.3).
In Vivo Activation
One of the earliest approaches to immunotherapy was the attempt to revert suppression
of cDCs in the tumor microenvironment by providing exogenous activation signals. Toll-like
receptors (TLRs) are one of the major pathogen- and damage-sensing pathways, with 13 different
TLRs present in mice (TLR1-TLR13) and the first 10 also present in humans. DC subsets display
differential TLR expression patterns in both species (103, 104). For example, in humans, pDCs
preferentially express TLR7 and 9, cDC1 preferentially express TLR3 and 8, and cDC2
preferentially express TLR1 and 6 (103). This means DCs preferentially recognize different
pathogenic/danger-associated signals and can be targeted with specific agonists, potentially with
the goal of optimally shaping the anti-tumor immune response. However, the identification and
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therapeutic use of of TLR agonists predates the classification of the cDC subsets, and limited
work has been done in this area.

Figure 1.3: Treatment modalities targeting DCs. A number of current treatment modalities aim to
address limited DC functionality in order to elicit or enhance anti-tumor immune responses.
Treatments that seek to improve the function of tumor DCs include in vivo activation, in vivo
expansion, and the blocking of inhibitory signals. Vaccination approaches that seek to bypass tumor
DCs and directly stimulate a de novo T cell response in the lymph nodes include whole cell vaccines,
antibody conjugated peptides, and free proteins or peptides.

In humans, TLR7 and TLR9 are among the more widely explored targets given their
capacity for inducing a type I IFN response. Topical TLR7 agonists including imiquimod and R848
have been shown to induce an immune response as well as promote some level of tumor control
in a variety of cancer types, including melanoma and breast cancer (105-107). Indeed, a number
of clinical trials are currently ongoing to test TLR7 agonists in breast cancer patients, with one
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having observed immune-mediated rejection of skin metastases following treatment with
imiquimod (105). Topical application carries a clear drawback, in that it can only reasonably be
used in situations where either the induction of a systemic immune response will be able to induce
tumor control, or where tumors are close enough to the body’s surface that a local immune
response can be induced. As a result, TLR7 agonists with non-topical application methods are
also under development. One such agonist is 852A, which has been shown to induce CXCL10
and IL-1RA production, although minimal tumor control was observed in initial clinical trials (108,
109). In addition to TLR7 activation, DCs can be targeted via TLR9 agonists (103), with activation
of TLR9 using CpG oligodeoxynucleotides (ODNs) causing pDC maturation and cytokine
production. The classes of CpG ODNs have different routes of administration and produce unique
downstream effects (103). In addition to CpG ODNs, a novel TLR9 agonist, IMO-2125, has also
been shown to engage TLR9 leading to downstream immune signaling and suppression of A20
lymphoma and CT26 colon carcinoma tumor models (110).
TLR3 and TLR8 are preferentially expressed by cDC1, which, owing to their established
role in anti-tumor immunity, makes them attractive therapeutic targets (103). Poly[I:C] is one of
the most well-known TLR3 agonists and administration is effective in inducing cDC1 maturation
as well as production of IL-12, type I IFNs, and chemokines. However, as it is not well-tolerated
clinically (111), variants have been developed that aim to reduce the toxicity of poly(I:C)
administration. One such variant is poly-ICLC, an RNAse resistant form of poly(I:C) that leads to
immune activation and some tumor responses, either alone or as an adjuvant to conventional
therapies (112, 113). Poly(I:C12U), another poly(I:C) variant, introduces unpaired bases in order
to increase the degradation rate of the drug in an effort to reduce adverse effects (114, 115). In
addition to TLR3, cDC1 also express TLR8, which can be targeted with the TLR7/8 agonist
mentioned previously, R848. Agonists of TLR8 alone are also in development. For example, VTX2337 was shown to activate cDC1 and monocytes (116) and was well-tolerated in phase I clinical
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trials, although progression free survival was unchanged in a phase II trial conducted in squamous
cell head and neck cancer (103, 117).
STING (stimulator of interferon genes) mediates type I IFN responses following
recognition of cytosolic DNA by cGAS (cyclic GMP-AMP synthase) and production of 2’3’-cGAMP
(118). Host STING is required for the induction of anti-tumor immunity, as STING-deficient mice
fail to develop spontaneous immunity against immunogenic tumor lines and show reduced
responses to radiation therapy (119, 120). STING knockout mice also exhibit increased
susceptibility to inflammation-associated carcinogenesis following administration of AOM/DSS to
induce colitis (121, 122). It is currently unclear whether STING expression by cDCs or other host
cells is important for promoting an immune response, and the specifics of the tumor model and
therapy being evaluated will likely impact the underlying biology. For example, blockade of CD47
promotes uptake of tumor cells by SIRPα + cDC2, leading to activation of the cGAS-STING
pathway (123), whereas in other tumor models it is production of 2’3’-cGAMP by tumor cells that
is responsible for activation of host STING (124). Regardless, the intratumoral injection of STING
agonists such as 2’3’-cGAMP and DMXAA can induce tumor rejection, both alone and in
combination with other therapeutic modalities (125, 126).
Despite the pre-clinical efficacy of intratumoral injection of STING or TLR agonists, single
agent efficacy in the clinic has remained elusive. This has hampered development of TLR
agonists in the past, but in the age of cancer immunotherapy these are now being reevaluated as
part of combinatorial therapies. For instance, a recent pre-clinical study showed that treatment
with the TLR9 agonist CpG led to increased OX40 expression on CD4 + T cells (127). Accordingly,
while intratumoral injection of CpG alone led to rejection of the directly treated tumor, the addition
of an OX40 agonist antibody lead to the clearance of contralateral tumors (127), and a phase I
study testing this combination in non-Hodgkin’s lymphoma is currently underway (NCT03410901).
As STING agonists have been developed more recently, these trials are already incorporating
anti-PD-1 into their phase I treatment arms (e.g., NCT03010176). That said, it remains to be seen
18

if this approach will be successful, and the development of systemic therapies targeting these
pathways will be important to expand treatments beyond accessible tumors (128).
Blocking Inhibitory Signals
Extracting murine cDCs from tumors allows them to activate and restimulate CD8 + T cells
(48), implicating the suppressive microenvironment as a key regulator of cDC function. An
alternative approach to enhance the activation state of tumor cDCs is therefore to block inhibitory
pathways that reduce cDC functionality. One advantage of this approach is that it allows for
systemic administration of inhibitors, as opposed to the local administration required for many
immune agonists. One of the first examples of this is targeting vascular endothelial growth factor
(VEGF), as VEGF inhibits DC maturation and prevents an effective anti-tumor immune response
(129). VEGF inhibitors are already in clinical use to inhibit angiogenesis, and evidence indicates
that antibodies against VEGF enhance the anti-tumor immune response by counteracting DC
inhibition (130, 131). This is supported by several pre-clinical studies showing that inhibitors of
VEGF increase immune function and decrease the rate of tumor growth (131-133). VEGF
inhibition has also been shown to enhance DC maturation in human patients (134), suggesting
that this may contribute to the efficacy of VEGF inhibitors in the clinical setting. However, it should
be noted that the impact of VEGF on the vasculature and other immune populations may be more
relevant to the immune impact of VEGF pathway inhibitors (135).
Another potent immunosuppressive signal in the tumor microenvironment is IL-10, which
can be produced by tumor cells, macrophages, regulatory T cells, as well as other components
of the stroma. Using isolated human DCs in co-culture with human melanoma cell lines,
researchers have shown that IL-10 prevents DC maturation and induces a tolerogenic phenotype
(136). Blockade of IL-10 in pre-clinical models, either directly or via depletion of macrophages,
has been shown to improve CD8 + T cell mediated anti-tumor immune responses in both murine
and human systems (77, 136-138). At least in a mammary tumor model, this has been directly
linked to the ability of IL-10 to suppress IL-12 production by cDC1s, reducing the percentage of
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CD8+ T cells that display a cytotoxic effector phenotype (77). TIM-3 expression by cDCs has also
been shown to prevent response to chemotherapy in several tumor models (139, 140). How this
occurs in unclear, but may relate to TIM-3 binding to high mobility box 1 protein (HMGB1) and
limiting response to nucleic acids (140). Thus, while anti-TIM-3 antibodies can promote response
to PD-1/L1 blocking by reducing T cell exhaustion (141, 142), TIM-3 blockade might prove
efficacious even in patients with tumors that do not display substantial T cell infiltration.
Regulation of immunometabolism to increase anti-tumor immunity has been an increasing
focus of cancer research. Although our understanding of basic immunometabolism is still
evolving, several key insights have been made that are of relevance to tumor-associated DCs
(129, 143). First, DC expression of indoleamine 2,3-dioxygenase 1 (IDO1) is thought to reduce Ltryptophan availability by converting it to L-kynurenine, leading to an increase in the suppressive
capacity of regulatory T cells (144, 145). That said, IDO1 can be highly expressed by tumor cells
themselves, and evidence that IDO1 expression by tumor DCs is a major mechanism of immune
suppression is lacking. Several IDO1 inhibitors have also failed to demonstrate efficacy over the
past few years, raising questions about the validity of this approach. Second, lipid accumulation
in DCs has been shown to limit the function of DCs via interference in antigen processing and
subsequent antigen presentation (146, 147). Accumulation of lipids in tumor associated DCs is
promoted by DC specific activation of the endoplasmic reticulum (ER) stress sensor XBP1 (148).
DC-specific siRNA silencing of XBP1 led to decreased lipid accumulation by DCs and enhanced
immune-mediated tumor control in mouse models of ovarian cancer (148). Although further
research will be required before ER stress can be effectively targeted to treat cancer, it is an
active area of investigation.
In Vivo Expansion
Tumor cDCs are relatively infrequent in human and murine epithelial malignancies (48,
82, 139). Thus, increasing the number of intratumoral cDCs represents an alternative approach
to increasing the cumulative function of the population. Rather than the injection of exogenously
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expanded and activated cDCs (DC vaccinations, described below), it has been shown in preclinical studies that systemic injection of Flt3L leads to systemic expansion of the cDC1
population, increasing the number of these cells within B16 melanoma and significantly delaying
tumor growth (61). This approach also showed promise in increasing both the number of cDCs in
pancreatic tumors and overall control of pancreatic tumor lesions in an autochthonous disease
model, highlighting the importance of DC infiltration and expansion even in cancer types with
typically low immune infiltration (149). Combined administration of Flt3L with TLR agonists,
STING agonists, radiation, and/or checkpoint blockade results in additional tumor control, even in
advanced tumors (61, 62, 149, 150). This approach is being tested clinically in several tumor
types, including metastatic breast cancer and non-Hodgkin’s lymphoma (NCT03789097,
NCT01976585). The key advantage of this therapy is the potential for targeting a wider range of
antigens, rather than those selected for vaccination, bypassing the need for patient-specific
vaccine development. In addition, both systemic T cell activation and local T cell infiltration are
enhanced by this combination, increasing the potential for synergy with other immunotherapies.
Dendritic Cell Vaccines
In contrast to in vivo expansion, whole-cell DC vaccines rely on exogenous maturation
and/or expansion of moDCs or cDC precursors (figure 1.4), although most trials utilize moDC due
to the rarity of cDCs or pre-DCs (151). These cells are isolated from a patient’s peripheral blood,
loaded with tumor lysate or tumor antigens, and matured using various cytokine cocktails (152,
153). Whole cell DC vaccines are associated with limited toxicities, are therefore considered a
relatively safe therapeutic approach, and are being extensively evaluated in the clinic (153, 154).
Multiple vaccine formulations can lead to increased antigen-specific T cell responses. There have
even been trials in AML involving the fusion of cancer cells with autologous moDCs (155).
However, the presence of an immune response has not correlated with clinical efficacy (156), with
response rates in general between 8 and 15% in single arm trials (154). The only whole cell DC
vaccine approved by the FDA to date is sipuleucel-T, which consists of isolated PBMCs cultured
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with a GM-CSF/prostatic acid phosphatase fusion protein (157). This approval to treat metastatic
prostate cancer was based upon a 4.1 month improvement in overall survival without an
accompanying delay in disease progression (157), and there have been questions about whether
the vaccine is truly efficacious, leading to limited usage in the clinic.
Given the ability of most vaccines to induce an immune response against a specific
antigen, it is unclear why vaccines have shown limited efficacy to date. One possibility is that the
immunosuppressive microenvironment of the tumor blocks T cell infiltration, survival, or effector
function. Several pre-clinical studies have shown that PD-1 and/or CTLA-4 blockade can improve
tumor control in combination with tumor cell vaccines (158, 159). Similarly, in a mouse mammary
tumor model, the efficacy of a HER2-loaded BMDC vaccine was improved by sequential anti-PD1 therapy (160). Treatment with DC vaccines has also been shown to augment responses to
standard-of-care therapy (161). Clinical trials have begun to evaluate the efficacy of combining
DC vaccines with standard-of-care therapies and of vaccination with different DC subsets. In
glioblastoma, a phase III clinical trial to assess the efficacy of a whole cell DC vaccine
administered

in

combination

with

tumor

resection,

temozolomide,

and

radiotherapy

(NCT00045968) exhibited safety and potential efficacy based on interpretation of early results
(162). In contrast, a phase III trial of tumor-RNA loaded whole cell vaccines in combination with
sunitinib following surgical debulking for the treatment of renal cell carcinoma (NCT01582672)
was terminated early due to a lack of efficacy.
The limited efficacy of DC vaccines could also be a result of protocols that do not produce
the optimal T cell response. GM-CSF maturation of PBMCs produces moDCs that are limited in
their capacity to migrate to lymph nodes (163, 164), and several studies have shown endogenous
DCs are actually required for T cell priming following administration of moDC vaccines (165-167).
Murine cDC1s have been used in a vaccine in at least one study (168), but whether this is a viable
approach in the clinic remains to be determined, particularly given the paucity of circulating,
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Figure 1.4: Process of generating whole cell DC vaccines. Monocytes (or less commonly,
immature cDCs) are isolated from the patient's peripheral blood. In the case of monocyte isolation,
immature moDCs are generated by culturing the isolated cells in GM-CSF and IL-4. Once
immature DCs are obtained, they are matured/activated using a variety of cytokine cocktails and
pulsed with tumor antigen or tumor fragments. The matured DCs are then injected back into the
patient, usually via subcutaneous (s.c.) or intradermal (i.d.) injections, although intravenous (i.v.)
or direct injection into lymph nodes has also been used.

mature cDC1 in human peripheral blood (151, 169). Instead, studies have largely focused on
improving baseline efficacy by assessing activation with different maturation cocktails. For many
years, the ‘gold standard’ maturation cocktail consisted of TNFα, IL-1β, IL-6, and PGE2 (152).
However, PGE2 induces T regulatory cells and lowers IL-12 production, so methods of maturation
which omit it are being explored. For example, an interferon cocktail along with TLR3, TLR7, and
TLR8 agonists produced superior T cell mediated cytotoxicity against a breast cancer cell line
(170), while the combination of TNFα, IL-1β, IFN-γ, and a TLR7/8 agonist induced higher levels
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of the T cell chemoattractants CXCL9/10 (171). At the same time, the ‘gold standard’ cocktail
induces the highest level of DC migratory capacity (152). Given that increased DC migration to
the lymph node following vaccination has been associated with increased overall survival in a
small cohort of patients (172), it is unclear which approach would be better at promoting tumor
control. DC migration to the lymph node can also be directly enhanced by pretreating the injection
point with DC activating agents such as tetanus toxoid and CCL3, or TLR agonists such as
imiquimod or poly-ICLC (172, 173). The number of DCs injected also plays a role in achieving
optimal responses, with 106-107 DCs per injection representing the optimal range for efficacy (174,
175). Given the range of approaches, it remains to be seen which, if any, will produce anti-tumor
responses that can induce tumor regression, either alone or in combination with other therapeutic
modalities.
Peptide/Protein Vaccines
Another possible reason for the failure of many DC vaccines may be the reliance on
overexpressed or tissue-specific antigens (e.g., NY-ESO-1, MUC1, MAGEA3, MART1, HER2). In
addition to their use in DC vaccines, these antigens have been fused to DC-targeting antibodies
against Clec9a, DEC205, or DC-SIGN to enhance their ability to induce an immune response
(154). DEC205-fused tumor-associated antigens demonstrate improved ability to induce T cell
responses over administration of free antigen (176, 177). Additionally, partial clinical responses
were observed following administration of DEC205-fused NY-ESO and TLR agonist adjuvants in
a phase I clinical trial (178). While targeting Clec9a generally induces tolerance, different
adjuvants can be added in order to drive immune responses (156). For example, when combined
with poly(I:C) and other adjuvants, Clec9a-fused antigens induce CD4- and CD8-mediated antitumor immunity (179, 180), while fusion of human IFNα to Clec9a led to an anti-tumor response
that was improved by treatment with checkpoint blockade in the murine 4T1 mammary tumor
model (181). Peptide fusions to antibodies against several other DC surface proteins are also in
pre-clinical and clinical development (154). Given that different DC subsets can be targeted using
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antibodies against specifically expressed surface proteins, this represents another mechanism by
which the anti-tumor immune response could be optimally shaped to induce the best outcomes
for a given patient. However, one of the most recent advances in the development of cancer
vaccines has been the ability to generate vaccines with patient-specific neoantigens. Although
expensive and technically challenging, neoantigen vaccines are safe and able to induce strong
systemic T cell responses (182, 183). More importantly, complete, durable responses have been
observed in patients receiving neoantigen vaccines in combination with anti-PD-1 therapy in early
phase clinical trials. Dozens of studies are now underway testing neoantigen vaccines either
alone or in combination with ICB (e.g., NCT02950766, NCT03639714, NCT03953235,
NCT04161755, NCT03359239).
Discussion
A substantial body of research has established the fact that dendritic cells, especially
cDC1, play a key role in driving anti-tumor immune responses (48, 59, 63, 75, 139). However,
studies have also shown that as a result of incomplete maturation (48, 61) or immunosuppressive
factors within the tumor microenvironment (77, 184), dendritic cells within the tumor may not be
functioning optimally. As discussed earlier in this chapter, however, ongoing pre-clinical and
clinical research aims to improve DC responses, either by improving endogenous DC function,
increasing the number of DCs available to initiate anti-tumor immunity, or a combination thereof.
Approaches such as these are likely to be required in order to engage the immune response and
optimally treat patients for whom current immunotherapies are unsuccessful. Of particular
importance, while the majority of currently approved immunotherapies target the T cell arm of the
immune response, dendritic cell-targeted therapies will provide an alternative approach, which
may provide additive efficacy when combined with T cell-based therapies.
With that in mind, the work described herein aims to identify a pathway by which cDC1
can be targeted in breast tumors (which are, on the whole, poorly responsive to immunotherapy
(185)) (Chapter 2). As therapies are unlikely to be used in isolation, it is also important to fully
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understand the mechanism by which an individual therapy functions, so that it can be rationally
combined with other therapeutic agents. We therefore also aim to understand the mechanism by
which our identified therapy (TIM-3 blockade) reduces the rate of tumor growth (Chapter 3). Taken
together, these findings have the potential to impact treatment decisions for breast cancer, and
to shape our understanding of intratumoral dendritic cell function.
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Chapter 2: TIM-3 Suppresses Both CXCL9 Expression by Dendritic Cells and Response
to Chemotherapy2
Introduction
Knowing that dendritic cells (DCs) play a key role in driving anti-tumor immunity, we
sought to determine whether there may be mechanisms that could be used to improve their
functionality, either through direct stimulation or through removing suppressive factors within the
tumor microenvironment. Previous work had shown that IL-10 production by macrophages
suppresses DC function, and that blocking this pathway improves response to chemotherapy (77).
Based on this finding, it was clear that DC function could be therapeutically modulated, similar to
the modulation of T cell function observed with the use of checkpoint blockade inhibitors. As such,
a flow cytometry screen was performed to examine expression of common inhibitory receptors by
immune subsets within the tumor microenvironment of late-stage mammary tumors in MMTVPyMT transgenic mice on the FVB/NJ background (139). From this screen, T cell immunoglobulin
and mucin domain-containing molecule (TIM)-3 was found to be expressed at high levels on
CD103+ cDC1s compared to other immune populations (139).
TIM-3 is a receptor that was originally described as being expressed on IFN-γ-producing
helper CD4+ T cells (Th1) and cytotoxic CD8 + T cells (186, 187). More recently, TIM-3 has also
been shown to be expressed on regulatory T cells (Tregs) as well as on several innate immune
cells, including DCs, NK cells, and monocytes (187). In tumors, chronic infection settings, and
graft-versus-host disease, co-expression of TIM-3 expression is associated with a population of
highly active and/or exhausted T cells, particularly when co-expressed with PD-1 (142, 188-191).

2

A note to the reader: portions of this chapter have been previously published in the journal
Cancer Cell (de Mingo Pulido et al, 2018; (132)) or have been accepted for publication in the
journal Journal of ImmunoTherapy of Cancer.
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When expressed on DCs, TIM-3 has been shown to facilitate the uptake of apoptotic material,
and to enhance cross-presentation of antigens by cDC1. In addition, TIM-3 has been shown to
inhibit activation of nucleic acid sensing toll-like receptors in tumor-associated DCs (140).
Blocking antibodies against TIM-3 have also been shown to promote TH1 responses through
reductions in cell death and exhaustion in models of auto-immunity and infection (186, 192), in
addition to increasing IFN-γ expression in vivo and ex vivo (142, 189-191). Furthermore, high
levels of TIM-3 expression have recently been associated with poor pre-operative responses to
therapy in TNBC (193). As a result, several therapeutic antibodies have been developed against
TIM-3 in order to enhance T cell-mediated immunity. We therefore sought to evaluate the efficacy
of TIM-3 blockade in the setting of mammary tumors as well, in order to investigate the hypothesis
that TIM-3 expression by dendritic cells in this context was suppressing DC functionality.
Using a blocking antibody against TIM-3 we found no impact on tumor growth alone;
however, combining TIM-3 blockade with standard-of-care paclitaxel (PTX) chemotherapy
significantly reduced tumor growth compared to PTX alone (139). Improved response to
chemotherapy was dependent upon the presence of CD8 + T cells, despite a lack of TIM-3
expression by these cells. This was not due to a change in T cell infiltration or activation state.
Instead, we observed higher CD8 + T cell effector function, as measured by increased IFN-γ
expression, along with a small increase in granzyme B expression. These data suggested that
TIM-3 blockade therapy improves the ability of cDC1s to promote or sustain T cell effector
function. Here we sought to determine the mechanism by which this occurs.
Materials and Methods
Animal Studies
Animals were maintained in the University of South Florida (USF) Department of
Comparative Medicine barrier facility, and all animal studies were approved by the USF
Institutional Animal Care and Use Committee (IACUC) under protocols IS00004539, IS00008519,
IS00002135, or IS00005957 (see appendix A). Wild type C57BL/6J mice were bred in house or
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ordered from The Jackson Laboratory (stock 000664). Cxcl9-/- (stock 030285) and Cxcl10-/- (stock
006087) mice were ordered from The Jackson Laboratory. Xcr1-DTR (XCR1tm2(HBEGF/Venus)Ksho)
mice (194) were obtained directly from Matthew Krummel at UCSF. In indicated experiments,
bone marrow transfer was used to generate sufficiently powered, age-matched experiments. For
bone marrow transfer experiments, 6-8 week old female mice were sub-lethally irradiated with 2
doses of 500 rad using a cesium irradiator, 24 hours apart. 6-24 hours after the second dose,
mice received intravenous transfer of 50 μL bone marrow cells, depleted of red blood cells and
suspended in phosphate buffered saline (PBS) at a density of 4 x 10 7 cells/mL. Irradiated mice
were maintained on enrofloxacin – a fluoroquinolone antibiotic – added to the drinking water at a
concentration of 0.1 mg/mL and available ad libitum for the duration of the experiment, beginning
after the second dose of irradiation. Tumors were implanted 6 weeks after bone marrow transfer
to allow for immune reconstitution. Tumors were orthotopically implanted in the right 2/3 mammary
fat pad of female mice, using a single cell suspension isolated from mammary tumors of MMTVPyMT mice combined 1:1 with Matrigel (Corning). Treatment was initiated when tumors reached
approximately 100 mm 3 (length x width x height). Mice were dosed with anti-TIM-3 antibody (clone
RMT3-23), or anti-PD-L1 (clone 10F.9G2; Bio X Cell) alone or in combination with paclitaxel (PTX)
as indicated in the figure legends. Briefly, 1 mg antibody per mouse was administered via
intraperitoneal injection 5 days prior to the initiation of PTX therapy, with follow-up doses of 0.5
mg per mouse every 5 days, concurrently with retro-orbital administration of 10 mg/kg PTX (when
PTX was used). Mice were euthanized and excluded from the study if ulceration greater than 0.5
cm occurred.
Generation of Bone Marrow-Derived DCs (BMDCs)
In order to generate BMDCs, mice were euthanized by CO 2 inhalation followed by cervical
dislocation. Tibias and femurs were removed and stored in PBS or media at 4˚C until processing.
To extract the bone marrow, muscle and tissue was removed from the bones using forceps and
surgical scissors. Once cleaned, one end of the bone was removed, leaving an opening from
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which bone marrow could be extracted. For each bone, a set of nested Eppendorf tubes was
prepared as follows: 100 μL media or PBS was placed into a 1.5 mL Eppendorf tube. A 0.6 mL
Eppendorf tube was then placed inside the larger tube, and a 20- to 22-gauge needle was used
to puncture a hole in the base of the 0.6 mL tube. A bone was then placed into the smaller tube,
with the open side facing down. Tubes were centrifuged at 4000 x g for 1.5 min. After
centrifugation, the bone marrow cells should be pelleted in the liquid in the larger tube. The smaller
tube and the bones were then discarded. Bone marrow was collected and resuspended in red
blood cell lysis buffer (155 mM NH4Cl + 12 mM NaHCO3 + 0.1 mM EDTA) before centrifugation
at 400 x g for 5 minutes. Cells were then counted and plated at a density of 1.5 to 2 x 10 6 cells/mL
in complete media (RPMI + 10% FBS + 1% penicillin/streptomycin + non-essential amino acids
(from 100x stock) + sodium pyruvate (from 100x stock) + 55 μm beta-mercaptoethanol (added
fresh immediately prior to use), supplemented with specific concentrations of Flt3L and/or GMCSF, depending on the type of BMDC being generated. For GM-CSF BMDCs (which have a more
monocyte/macrophage-like phenotype (195)), media was supplemented with 10 µg/mL murine
GM-CSF, and cells are cultured for 7 days, with media added or changed at days 3 and 6 (to
maintain density of approximately 2 x 10 6 cells/mL. For Flt3L BMDC (which are a mix of cDC1
and cDC2), media is supplemented with 100 ng/mL Flt3L-Fc (BioXCell), and cells are cultured for
8 days without disturbance. For iCD103 BMDCs (which are >90% CD103+ cDC1 (196)), media is
supplemented with 200 ng/ml Flt3L-FC and 3.33 ng/mL GM-CSF, and cells are cultured for 1316 days. For these cells specifically, media is added on day 5 or 6 to minimize apoptosis. On day
9, the non-adherent portion of the culture is collected and diluted back to 1.5 to 2 x 106 cells/mL
in media supplemented with Flt3L-Fc and GM-CSF as on day 1.
Immunohistochemistry (IHC)
Following treatment, mice were cardiac perfused with PBS containing 10 U/mL heparin to
remove peripheral blood, and tissues were resected and placed in formalin for 24 hours at room
temperature for fixation. Tissues were then placed in cassettes and moved through increasing
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concentrations of ethanol washes (30%, 50%, 70%) before storage in 70% ethanol at 4˚C prior to
embedding in paraffin and sectioning. Formalin-fixed paraffin embedded (FFPE) Sections were
deparaffinized and re-hydrated prior to staining by progressive incubations in alcohol (2 x 5 min
in 100% xylene, 2 x 3 min in 100% ethanol, 1 min in 95% ethanol, 1 min in 80% ethanol, ≥ 5 min
in H2O). Slides were then washed in PBS (2 x 5 min) prior to antigen retrieval using EDTA retrieval
buffer (1 mM EDTA + 0.05% Tween 20 in de-ionized water, pH 8.0) or citrate retrieval buffer (10
mM sodium citrate + 0.05% Tween 2 in de-ionized water, pH 6.0). Slides were incubated in
retrieval buffer in a steamer for 30 min or an Instant Pot at high pressure for 15 min, followed by
cooling in a room temperature water bath for at least 30 min (until buffer reaches approximately
room temperature). Endogenous peroxidase activity was then blocked by incubation in 200 mL
MeOH + 4 mL 30% H2O2 for 40 min at room temperature while shaking. After washing 2 x 5 min
in PBS, slides were incubated in blocking buffer (5% horse serum + 1 mg/mL bovine serum
albumin (BSA) + 0.05% Tween 20 PBS) for 1 hour at room temperature in a humidified chamber.
Slides were then incubated with primary antibody diluted in blocking buffer either at room
temperature for 2 hours or overnight at 4˚C. Following incubation with primary antibodies, slides
were washed 3x in PBS prior to incubation with the appropriate secondary antibody (anti-mouse
ImPRESS [MP7401], anti-goat ImPRESS [MP7405], anti-rat ImPRESS [mouse adsorbed;
MP7444], anti-rabbit ImPRESS [MP7402], all from Vector Laboratories) at room temperature for
1 hour. Slides were washed 3x in PBS prior to incubation with 3,3′-Diaminobenzidine (DAB).
Incubation times in DAB ranged from 30 seconds to 5 minutes depending on the primary antibody.
Finally, slides were counterstained by incubation with hematoxylin for 30 seconds. Slides were
dehydrated by progressive alcohol incubations (2 min in 95% ethanol, 2 x 3 min in 100% ethanol,
2 x 5 min in 100% xylene) prior to coverslipping with Cytoseal 60 (Fisher Scientific, 23-244257)
mounting media. Slides were allowed to dry overnight prior to scanning using a Leica Aperio AT2
scanner. Analysis of staining density was performed using nuclear staining, cytoplasmic staining,
or positive pixel count algorithms through Imagescope software, as indicated.
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Immunofluorescence (IF)
Using

formalin-fixed,

paraffin

embedded

tissues

prepared
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outlined
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‘Immunohistochemistry’, above, we also performed immunofluorescence staining to examine colocalization of certain markers. Slides were de-paraffinized and rehydrated, and antigen retrieval,
blocking, and primary antibody incubation were performed as described above. Following
incubation with the primary antibodies, slides were washed 3x in PBS for 5 min each, followed by
re-blocking for 5 minutes by incubation with blocking buffer. Then, slides were incubated with the
appropriate fluorescently labelled secondary antibodies at a 1:500 dilution in blocking buffer for 1
hour at room temperature. Slides were washed once in PBS prior to staining the nucleus with
Hoechst 33324, diluted 1:20,000 in blocking buffer for 15 min at room temperature. Following 3
washes in PBS, slides were coverslipped with either Prolong Gold (P36934, Thermo Fisher
Scientific) or Prolong Glass (P36980, Thermo Fisher Scientific) Antifade Mountants. Mounting
media was allowed to cure overnight at room temperature. Slides were then stored at 4˚C until
imaging at the indicated magnification using a Zeiss Axio Imager Z1. Where necessary,
thresholding was performed on entire images using either Zen Pro software (Zeiss) or Affinity
Designer (Serif).
Flow Cytometry
Mice were cardiac perfused with PBS containing 10 U/mL heparin to remove peripheral
blood. Single cell suspensions of tumor cells were prepared by mincing tumors and digesting with
50 U/mL DNAse I (Roche Life Sciences) and 1 ug/mL Collagenase A (Roche Life Sciences) in
Hank’s Buffered Saline Solution (HBSS), followed by passing the cell suspension through a 70
μm mesh filter to remove aggregates. Collagenase was omitted from the digestion buffer for
studies examining CXCR3 expression, as its inclusion prevented staining for CXCR3. Red blood
cells were removed by resuspending the tumor digest in red blood cell lysis buffer (155 mM NH 4Cl
+ 12 mM NaHCO3 + 0.1 mM EDTA). Cells were plated at a density of 2 x 106/mL in PBS in a 96
well plate for staining. Dead cells were stained by incubating a 1:1000 dilution of Zombie NIR
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(Biolegend #423107), Live/Dead Aqua (Fisher Scientific, #L34965), or Zombie UV (Biolegend
#423107) fixable viability dyes in PBS for 30 minutes at 4˚C. To minimize non-specific staining,
the cells were then incubated in a 1:500 dilution of Fc block (anti-mouse CD16/32, Biolegend
#156604). Immune populations were identified using a previously described gating strategy (77).
Extracellular staining was performed by diluting antibodies 1:400 in FACS buffer (PBS + 1 mg/mL
BSA + 1 mM ethylenediaminetetraacetic acid [EDTA]) and incubating cells for 30 minutes at 4˚C.
Cells were then fixed by incubating in BD Cytofix for 30 minutes at 4˚C. To perform intracellular
staining, cells were permeabilized using the BD Transcription Factor Buffer Kit (for panels that
included Ki67 staining) or BD Cytoperm (all other applications) according to manufacturer’s
directions. Data was collected with either an LSRII or a FACSymphony flow cytometer, and all
analysis was performed using FlowJo version 9 or 10 (FlowJo, LLC).
Quantitation and Statistical Analysis
Quantitation and statistical analyses were performed in Excel (Microsoft) and GraphPad
Prism version 7, 8, or 9 (GraphPad). Data points represent biological replicates and are shown
as the mean ± SEM unless otherwise indicated. Statistical significance was determined as
indicated in the figure legends. For growth curves significance was determined via 2-way ANOVA
with Tukey’s multiple comparisons test, with significance shown for the final data point. A 2-way
unpaired t-test or 2-way unpaired t-test with Welch’s correction was used for comparison between
groups with equal or unequal variance, respectively. Mann-Whitney and Kruskal-Wallis was used
for data failing the D’Agostino & Pearson omnibus normality test. Significance is shown as ∗p <
0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 as described in each figure legend. Correlation analysis in breast
cancer was performed using the GEPIA web server (197), which accesses data from The Cancer
Genome Atlas Network (198).
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Results
TIM-3 Blockade Promotes Chemokine Expression by Tumor cDCs
In order to determine a mechanism by which TIM-3 blockade functions in mouse
mammary tumors, we isolated macrophages and cDCs from orthotopically implanted PyMT
tumors and used the NanoString nCounter Mouse Immunology Panel to perform gene expression
analysis. We identified only five genes (Cxcl11, Cxcl10, Cxcl9, Tagap, and Cd40) that were
significantly altered (p < 0.05) and exceeded a 1.5-fold change in cDC1s from animals treated
with IgG2a/PTX versus αTIM-3/PTX (139). Of these, Cxcl9, Cxcl10, and Cxcl11 were also
upregulated in type 2 cDCs, but not in either the MHCII hi or MHCIIlo macrophage populations
(figure 2.1A).
Additionally, we observed that CXCL9 protein expression co-localized with the DC marker
LAMP3 in human breast tumors (figure 2.1B). Furthermore, CXCL9 and CXCL10 gene expression
was found to correlate with expression of LAMP3 and IRF8 in human breast tumors from the
TCGA data set, consistent with expression by human cDCs (figure 2.1C-D). We also examined
whether expression of CXCL9 and CXCL10 would correlate with cytotoxic T cell activity in human
breast tumors (figure 2.1C-D). Indeed, CXCL9 correlated strongly with CD8A and GZMB
(Pearson’s R = 0.81 and 0.67, respectively). CXCL10 expression was also found to correlate with
CD8A and GZMB, albeit to a lesser degree than CXCL9 (figure 2.1D). Together, these data
suggest that cDC production of CXCL9 and/or CXCL10 might play a role in promoting a cytotoxic
T cell response in human breast tumors.
To determine whether expression of CXCL9, CXCL10, or CXCL11 was required for the
reduction in tumor growth during TIM-3 blockade, we blocked or inhibited the receptor for these
chemokines, CXCR3, to determine if this prevented response to therapy. Indeed, adding a
CXCR3 blocking antibody (clone CXCR3-173) abrogated response to αTIM-3/PTX (figure 2.2A),
indicating that this chemokine-CXCR3 pathway is required for a therapeutic response. We
confirmed this finding using a chemical inhibitor of CXCR3, (±)AMG-487 (figure 2.2B). Taken
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together, these data indicate that TIM-3 blockade promotes CXCR3 chemokine ligand expression

Figure 2.1: CXCL9 is produced by dendritic cells in human breast tumors. (A) mRNA
expression levels in tumor macrophages and cDCs isolated from mice bearing orthotopically
implanted PyMT tumors 2 days following the second dose of PTX (day 7). Expression of Cxcl9,
Cxcl10, Cxcl11, and Il12b was determined by NanoString, with normalized counts displayed. n =
8 per group, data pooled from two experiments. (B) Immunofluorescence staining of CXCL9
(green) and CD163 (red, macrophage marker) or LAMP3 (red, dendritic cell marker) in human
breast tumors. DNA was visualized with Hoechst 33342 (blue). Three patient samples were
analyzed for each combination. (C-D) Log2 plots showing the correlation between CXCL9
expression (C) or CXCL10 expression (D) and DC-associated genes (LAMP3, IRF8) or lymphocyte
associated genes (CD8A, GZMB) in human breast cancer samples from the TCGA dataset. R
indicates Pearson’s R.
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together, these data indicate that TIM-3 blockade promotes CXCR3 chemokine ligand expression
by cDCs, leading to enhanced CD8 + T cell function and reduced tumor growth during PTX
chemotherapy.

Figure 2.2: CXCR3 signaling is required for response to αTIM-3/PTX. (A) Tumor volume
shown as a relative change from the initiation of chemotherapy (day 0) in MMTV-PyMT animals.
Mice were treated with an IgG 2a isotype control, αTIM-3, and/or αCXCR3 antibodies, together
with 10 mg/kg PTX as indicated. N = 8 mice per group, pooled over four cohorts. (B) Orthotopic
PyMT tumor volume in C57BL/6J mice treated with an IgG 2a isotype control, αTIM-3, and/or
(±)AMG-487 together with 10 mg/kg PTX as indicated. N = 5-7 per group, with one of two
representative experiments shown.
CXCL9 Expression by cDC1 is Required for Response to αTIM-3/PTX
Given that CXCR3 has three known ligands (CXCL9, CXCL10, and CXCL11), and that
both CXCL9 and CXCL10 were found to correlate with CD8A and GZMB, we next sought to
determine whether a single chemokine was specifically responsible for the CXCR3-dependent
response to αTIM-3/PTX. C57BL/6J mice harbor a frameshift mutation in Cxcl11, leading to a
premature stop codon and non-functional CXCL11 (199); therefore, we focused on the role of
CXCL9 and CXCL10 in driving response to αTIM-3/PTX. To generate sufficient numbers of agematched mice for the studies, we irradiated 6-week-old mice and transplanted them with either
wild-type C57BL6/J (WT), Cxcl9-/-, or Cxcl10-/- bone marrow. PyMT mammary tumors were then
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implanted after six weeks to allow time for immune reconstitution (figure 2.3A). Mice reconstituted
with Cxcl10-/- bone marrow responded similarly to treatment with αTIM-3/PTX as those
reconstituted WT bone marrow, indicating that CXCL10 was dispensable for efficacy (figure 2.3B).
In contrast, mice reconstituted with Cxcl9-/- bone marrow failed to respond to αTIM-3/PTX,
demonstrating the requirement of CXCL9 expression by the hematopoietic compartment (figure
2.3C).

Figure 2.3: CXCL9 expression drives response to TIM-3 blockade. (A) Diagram outlining the
experimental approach for the in vivo experiments in (B) and (C). Mice underwent total body
irradiation (TBI), followed by reconstitution with the indicated BM. 6 weeks following reconstitution,
PyMT tumors were implanted orthotopically. Antibody (Ab) treatment was initiated when tumors
reached 100 mm3, with paclitaxel (PTX) administered 5 days later, and repeated every 5 days,
concurrent with Ab administration. (B) Percent change in tumor volume from the start of PTX
administration in mice reconstituted with WT (left) or Cxcl10-/- BM (right). Merged data from 2
independent experiments; n ≥ 14 mice per group. (C) Percent change in tumor volume from the
start of PTX administration in mice reconstituted with wild type (WT, left) or Cxcl9-/- BM (right).
Merged data from 3 independent experiments; n ≥ 26 mice per group.
TIM-3 is primarily expressed on cDC1 in MMTV-PyMT orthotopically implanted tumors
(figure 2.4), and as such these cells are directly affected by TIM-3 blockade (139, 200). However,
cDC1s in tumors are relatively infrequent, representing <1% of CD45 + cells, and are not increased
by TIM-3 blockade (figure 2.5A). CXCL9 expression is also not limited to cDC1s, with expression
by macrophages and the cDC2 subset observed within untreated tumors (figure 2.5B). Therefore,
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Figure 2.4: TIM-3 expression within MMTV-PyMT mammary tumors. (A) Representative
histograms showing TIM-3 surface expression by immune subsets in orthotopically implanted
MMTV-PyMT tumors. (B) Quantification of TIM-3 surface expression by immune subsets in
orthotopically implanted MMTV-PyMT, shown as a percentage of the population. Data from 1
of 2 independent experiments, n = 5 mice.
to specifically investigate the importance of cDC1-produced CXCL9, we generated mixed bone
marrow (BM) chimeric mice reconstituted with a 50% mixture of Xcr1-DTR BM combined with a
50% mixture of either WT or Cxcl9-/- BM (Figure 2.6A). As XCR1 is expressed exclusively by
cDC1s, treatment with diphtheria toxin (DT) allowed us to selectively deplete this subset, leaving
only the WT or Cxcl9-/- cDC1s during administration of therapy (figure 2.6B-C). This allowed us to

Figure 2.5: Characterization of immune infiltrate in orthotopically implanted MMTV-PyMT
tumors. (A) Immune infiltration in PyMT tumors, shown as a percentage of the CD45 + immune
population. No significant difference between treatment groups was observed. Data from 1 of 2
independent experiments; n = 9 mice per group. (B) CXCL9 expression by myeloid populations
within tumors. Representative data from 1 of 2 independent experiments.
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interrogate the role of CXCL9 specifically in cDC1s, in addition to allowing tumors to develop in
the presence of Cxcl9-proficient Xcr1-DTR+ cDC1. As shown in figure 2.6D, while control mice
showed reduced tumor growth during treatment with αTIM3/PTX, mice receiving 50% Cxcl9-/bone marrow showed equivalent tumor growth whether treated with αTIM-3/PTX or IgG2a/PTX.
Taken together, these data demonstrate that cDC1 expression of CXCL9, but not CXCL10, is
critical for the control of mammary tumor growth during αTIM-3/PTX therapy.

Figure 2.6: cDC1 specific CXCL9 production drives response to αTIM-3/PTX. (A) Diagram
outlining the experimental approach for the in vivo experiments in (E-G). Diphtheria toxin (DT)
was administered every 2 days, starting 2 days prior to the first Ab dose, in order to deplete Xcr1DTR+ cDC1. (B) Quantitation of flow cytometry data showing the specific depletion of cDC1
following administration of DT. (C) Representative flow plot showing DT-mediated depletion of
Xcr1-DTR+ cDC1. Top panel, representative no DT control mouse; bottom panel, representative
DT-treated mouse. (D) Percent change in tumor volume from the start of PTX administration in
mice reconstituted with 50% Xcr1-DTR and 50% WT (left) or Cxcl9-/- BM (right). Data from 1 of 2
independent experiments; n ≥ 8 mice per group. Significance for B, C, and G determined by twoway ANOVA. Significance for E determined by unpaired t test. Significance shown as **p ≤ 0.01,
***p ≤ 0.001, n.s. = not significant.
Lymph Node Egress is not Required for Response to TIM-3 Blockade
CXCL9 is often associated with T cell infiltration into tumors (199), but we previously
described no change in the transgenic MMTV-PyMT animals treated with TIM3/PTX (139). As
noted earlier, we also observed no differences in CD4 + or CD8+ T cell infiltration following
treatment with TIM3/PTX in C57BL6/J animals bearing orthotopic PyMT tumors (fig. 2.5A).
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Therefore, instead of recruiting T cells into tumors, it was possible that CXCL9-expressing cDC1s
were instead migrating to the draining lymph nodes and promoting naïve T cell activation (201).
As one approach to evaluate the role of cDC1 antigen presentation within the draining
lymph node in driving response to αTIM-3/PTX, we made use of a PyMT tumor cell line expressing
the pH-insensitive fluorophore ZsGreen (PyMT-ZsGreen). Following treatment with TIM3/PTX
or IgG2a/PTX tumors and draining lymph nodes were harvested and the immune cells from each
tissue were examined for ZsGreen positivity. ZsGreen positivity was high in macrophages and
both cDC subsets within the tumor (figure 2.7A), although macrophages exhibited higher levels
of ZsGreen fluorescence, consistent with the dominant role of macrophages in phagocytosing
dead cell antigens (202). However, no differences in ZsGreen uptake by tumor myeloid cells were
observed between treatment groups, suggesting that TIM3/PTX does not affect uptake of tumorderived antigens.
In the lymph nodes, in contrast, treatment with TIM3/PTX did affect levels of antigen
positivity within cDC subsets, with CD103 + migratory cDC1 from TIM3/PTX treated mice
exhibiting lower levels of ZsGreen positivity compared to those from IgG2a/PTX treated mice
(figure 2.7B). This was true without significant changes in the total percentage of CD103 +
migratory cDC1 in the lymph node (figure 2.7C). Reduced ZsGreen delivery to the draining lymph
nodes also presumably reduced transfer to CD11b+ cDC2, resulting in lower ZsGreen positivity
within this population as well (63). The reason for this reduced antigen delivery was unclear, as
cDCs in the tumor did not display altered levels of CCR7 following αTIM-3/PTX therapy (figure
2.7D). When we depleted Ccr7-proficient XCR1+ cDC1s from mice using the mixed BM chimeric
approach, we found that these mice retained a response to αTIM-3/PTX (figure 2.7E-F). Only
when the depletion of Ccr7-proficient XCR1+ cDC1s was performed prior to tumor implantation
was therapeutic efficacy completely blocked, as expected due to the role of these cells in
establishing the initial anti-tumor CD8+ T cell response in the draining lymph nodes (63). Overall,
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Figure 2.7: TIM-3 blockade does not promote antigen presentation in the draining lymph
nodes. Mice bearing orthotopic PyMT-ZsGreen or PyMT (no fluorescence control) tumors were
treated with αTIM-3/PTX or IgG2a/PTX. Two days after the second dose of chemotherapy, mice
were euthanized and tumors and draining lymph nodes were collected for analysis. (A)
Representative ZsGreen within the major tumor-associated APC subsets, mean fluorescence
intensity (MFI), and percent positivity are shown. Representative data from 1 of 3 independent
experiments, n=9-10 mice per treatment group. (B) Representative ZsGreen within lymph node
cDC populations, along with percent positivity are shown. Representative data from 1 of 3
independent experiments, n=9-10 mice per treatment group. Significance determined by one-way
ANOVA and shown as *p ≤ 0.05, **p ≤ 0.01. (C) The total CD103 + migratory cDC1 population
within the draining lymph nodes, shown as a percentage of CD45 + cells. (D) Percent of tumor
CD103+ cDC1 staining positive for CCR7 in the treatment groups. Representative staining is
shown to the right. One of 2 representative experiments shown, n = 7 mice per group. (E) Diagram
outlining the experimental approach for the in vivo experiments in (F). Diphtheria toxin (DT) was
administered every 2 days, starting 2 days prior to tumor implantation or 2 days prior to the first
Ab dose, to deplete Ccr7-proficient Xcr1-DTR+ cDC1. (F) Percent change in tumor volume from
the start of PTX administration in mice reconstituted with 50% Xcr1-DTR and 50% Ccr7-/- BM. Data
merged from 2 independent experiments, n = 7-10 mice per group. Significance determined by
two-way ANOVA and shown as *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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these data support TIM-3 blockade enhancing the ability of DC1s to promote CD8 + T cell effector
function within tumors, while also highlighting the critical role of lymph node migration for inducing
and sustaining a T cell response against tumors. As another approach to determine if there was
a role for cDC1 and T cell interactions in the draining lymph nodes, we treated mice with the S1P
agonist FTY720 (figure 2.8A). As lymph node egress by T cells is governed by the S1P receptor,
FTY720 traps T cells in the secondary lymphoid organs and blocks a de novo T cell response
from acting on tertiary organs. To determine if TIM-3 blockade was promoting a systemic immune

Figure 2.8: Treatment with FTY720 does not prevent response to αTIM-3/PTX. (A) Diagram
outlining the experimental approach for the in vivo experiments in (B). (B) Relative tumor volume
in MMTV-PyMT animals treated with IgG2a/PTX or αTIM-3/PTX in combination with FTY720 or
DMSO as indicated. N = 7-8 mice per group, pooled over four cohorts. Data shown as mean ±
SEM; **p < 0.01, with significance determined by two-way ANOVA. (C-D) Percentage of
CD3+CD4+ (C) or CD3+CD8+ (D) T cells within the lymph nodes (LN), spleens, and tumors of
animals bearing orthotopically implanted MMTV-PyMT tumors treated with DMSO or FTY720 for
7 days. Data merged from 3 experiments.
response, mice were dosed with FTY720 at the start of antibody treatment. This allowed the
natural T cell response to develop and become established before therapy. FTY720 had no
impact on response to PTX or TIM-3 blockade (figure 2.8B), and did not affect the number of T
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cells present in the tumor (figure 2.8C-D). Taken together with the experiments making use of
PyMT-ZsGreen tumors, these data suggest that TIM-3 blockade promotes CXCL9 expression by
intratumoral cDCs, which enhances the functional activity of T cells already present within tumors.
TIM-3 Expression in Breast Tumors
To characterize TIM-3 expression in human cancer, FFPE tumors were first stained for
TIM-3 via immunohistochemistry (IHC). As shown in figure 2.9A, we observed positive TIM-3
staining in several tissue regions, including stromal regions, necrotic areas, tertiary lymphoid

Figure 2.9: Immunohistochemistry staining to examine TIM-3 expression in human tumor
samples. (A) TIM-3 immunohistochemistry in human breast tumor samples. Representative
images from 18 patients display positive staining in stromal regions (i), necrotic areas (ii), tertiary
lymphoid structures (iii and iv), and adjacent normal tissue (v). Cellular positivity for TIM-3 is
shown at (vi), with the horizontal bar representing the mean. (B-D) TIM-3 immunohistochemistry
in human lung (B), prostate (C), and ovarian (D) tumor samples. Representative images from ≥ 8
patients display positive staining in tertiary lymphoid structures (i), stromal regions (ii), myeloid
cells (iii), and adjacent normal tissue (iv). Cellular positivity for TIM-3 is shown at (E), with a
horizontal bar representing the mean. Scale bar for B-D indicates 100 μm.
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structures, and adjacent normal tissue. The level of positivity was variable, but low across the 18
tumors examined, ranging from close to 0% of cells expressing TIM-3 to nearly 2.5% of cells
figure 2.9A, panel vi). We performed similar analyses on deidentified human prostate, ovarian,
and lung tumors, and observed TIM-3 expression in all four settings, again at variable levels
(figure 2.9B-E). Although our IHC analysis was, in this case, limited to observation of the
expression patterns of the single protein TIM-3, this data allowed us to ascertain that TIM-3 was
expressed at the protein level within four different human tumor types.
In order to specifically identify the cell type within the tumor that was expressing TIM-3 in
human breast tumors, we made use of immunofluorescence (IF) staining, which allowed us to
examine the expression of multiple proteins simultaneously through the use of different
fluorescently labelled secondary antibodies. Focusing on the human breast tumors, we first
examined TIM-3 co-expression with general immune cells, tumor cells, and myeloid populations

Figure 2.10: Immunofluorescence staining to examine TIM-3 expression in human breast
tumors. (A) Immunofluorescent staining for TIM-3 (red) and CD45, cytokeratin, CD163, or
LAMP-3 (green) in human breast cancer. DNA was visualized with Hoechst 33342 (blue). Three
patient samples were analyzed for each combination. (B) Immunofluorescent staining for TIM3 (red) and CD3, CD4, or CD8 (green) in human breast cancer. DNA was visualized with
Hoechst 33342 (blue). Three patient samples were analyzed for each combination.
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(figure 2.10A). To do so, we stained for TIM-3 in combination with CD45 (fig. 2.10A panel i; to
evaluate expression by the immune population as a whole); pan-cytokeratin (fig. 2.10A panel ii;
to evaluate expression by tumor cells); CD163 (fig. 2.10A panel iii; to evaluate expression by
monocyte/macrophage lineage cells); and LAMP-3 (fig. 2.10A panel iv; to evaluate expression by
dendritic cells). Of these, we observed substantial co-staining with CD163 and LAMP-3 (figure
2.10A, panel iv), with some co-staining with CD45. Co-staining with LAMP-3 indicated that TIM-3
was expressed by dendritic cells within the tumor. Co-staining with CD163 indicated that TIM-3
was also expressed by tumor macrophages, which was consistent with the staining pattern
observed in transgenic PyMT tumors (139), but less so in the C57BL6/J PyMT orthotopic model
(fig. 2.4).
As TIM-3 has previously been reported to be co-expressed by activated CD4 + and CD8+
T cells (and indeed, was first described as expressed on these populations (186, 187)), we also
chose to specifically examine TIM-3 co-expression by these cells (figure 2.10B). We co-stained
tumor sections for CD3, CD4, and CD8 (to look at the T cell population as a whole, or the CD4 +
and CD8+ T cell populations specifically). Minimal co-localization of TIM-3 with any T cell marker
was observed (figure 2.10B), suggesting that in breast tumors, TIM-3 expression is largely
confined to the myeloid populations, specifically cDCs and macrophages.
Discussion
Within MMTV-PyMT tumors, we found that TIM-3 was highly expressed by cDCs, with
minimal expression by T cells in tumors and normal tissues. It has recently been described that
CD103+ cDC1 are necessary to promote antigen-specific T cell recruitment into immunogenic
melanoma tumors through their production of CXCL10 (75). However, in mammary tumors we
found that CD103+ cDC1 expressed minimal levels of Cxcl10, instead expressing high levels of
Cxcl9. Critically, Cxcl10 expression by bone marrow-derived cells was dispensable for response
to TIM3/PTX . Despite the increases in Cxcl9 expression that were observed following treatment
with TIM3/PTX , however, we did not observe an increase in infiltration by T cells. It is possible
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that this is due to the expression of multiple T cell-attractant chemokines within tumors (e.g. CCL5
and CXCL10), a small contribution of cDC-derived CXCL9 to total protein levels within tumors, or
selective recruitment of antigen-specific cells that was not detected when measuring bulk T cell
infiltration.
The CXCR3 axis has previously been shown to be required for response to adoptive cell
therapy (75) and PD-1 therapy (76). The work described in this chapter extends these findings
to TIM3/PTX by showing that cDC1-specific production of CXCL9 is required for control of tumor
growth following treatment with TIM3/PTX. As CXCL9 has been shown to be associated with T
cell infiltration in some contexts (75, 203-205), we explored the possibility that treatment with
TIM3/PTX was controlling tumors through increased T cell infiltration. However, no increases in
T cell infiltration were observed. Another role for CXCL9 that has been described is in organizing
responses in the lymph node (201). Using both the PyMT-ZsGreen tumor model to examine
antigen presentation in the lymph node and the addition of FTY720 to preclude exit of additional
T cells from the lymph node following initiation of treatment, we determined that lymph node
responses are likely not driving the observed reduction in the rate of tumor growth with
TIM3/PTX. Together, these observations instead point to a local, intratumoral role for cDC1
following treatment with TIM3/PTX.
One possibility for the finding that CXCL9 production by cDC1 does not drive T cell
infiltration in this model system is that intratumoral cDC1 are not producing enough CXCL9 to
signal outside of the tumor. Although the efficacy of chemokine signaling varies with both time
and concentration of the chemokine, the maximum distance at which a single cell can signal has
been estimated to be 250 microns (206). In a viral model, signaling through the CXCR3 axis was
also shown to be required for local virus control, with Cxcr3-/- CD8+ T cells specifically exhibiting
decreased contact with virus-infected cells without any differences in activation or homing (207).
It is possible that the CXCR3 axis is playing a similar role in the context of anti-tumor immunity,
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maintaining CD8+ T cells in close proximity to tumor cells, while other chemokines govern CD8 +
T cell infiltration into the tumor. As treatment with FTY720 did not affect response to TIM-3/PTX,
it suggests that our observations may be explained by local promotion of a CD8+ effector T cell
response. Interestingly, CXCL9 expression by cDCs has previously been described to mediate
DC-T cell clustering within lymph nodes (201). Since interactions between DCs and T cells are
infrequent within tumors (48), it is possible that increased expression of CXCL9 by cDC1 could
facilitate these interactions, thereby promoting T cell effector function.
Our findings further suggest that cDC1 within the tumor microenvironment are capable of
supporting intratumoral T cell function in situ, in addition to interactions in the lymph node.
Although this point has previously suggested in the literature, there is only limited evidence
supporting this assertion (77, 78, 208). Treatment with TIM-3 blockade, in this case, removes an
inhibitory signal preventing cDC1 production of CXCL9. As TIM3/PTX indirectly promotes a T
cell response (139), this implies that cDC1 production of CXCL9 is a driving mechanism behind
the ability of cDC1 to support CD8 + T cell effector function within the tumor. A potential explanation
for this finding is that CXCL9 produced by intratumoral cDC1 attracts intratumoral T cells, allowing
them to be in close enough proximity to the cDC1 to benefit from other signals. (This hypothesis
will be explored in chapter 3). TIM3/PTX does indeed function by bringing intratumoral CD8 + T
cells into proximity with cDC1, this has further implications for the design of combination therapies
making use of TIM-3 blockade. For example, TIM-3 blockade is currently in clinical trials in
combination with PD-1 for treatment of solid tumor malignancies (e.g., NCT03311412,
NCT03680508). It is possible that the timing of administration will play a role in the efficacy of
combination therapies, particularly if treatment with PD-1 leads to an expansion of the CD8 + T
cell population, as has been previously shown (76). In this case, it may make more sense to
administer PD-1 prior to TIM3, in order to expand the population of intratumoral CD8 + T cells
before bringing them close to cDC1 to promote optimal signaling. However, the mechanism of
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action, and therefore the recommended timing of administration, may also be dependent on tumor
type, particularly in cases where TIM-3 is expressed largely by the highly active and/or exhausted
T cell population (186, 188), rather than by cDC1, as is the case here. As such, it is important to
fully understand the immune compartment of a given tumor type prior to attempting to combine
agents, in order to provide the best likelihood of effective treatment.
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Chapter 3: TIM-3 Blockade Promotes Intratumoral Dendritic Cell and T Cell Interactions in
an IL-12 Dependent Manner3
Introduction
Despite the promise of immune checkpoint blockade (ICB) therapy as a treatment for
cancer, response rates remain low, particularly for certain types of malignancies. For example,
triple-negative breast cancer (TNBC) exhibits an objective response rate to PD-L1 therapy of
less than 10% (185). Response to PD-1 or PD-L1 is usually linked to the presence of PD-L1expressing tumor cells. However, a recent phase III trial observed improvements in progression
free survival (PFS) with a PDL1 combined positive score (CPS; the number of PD-L1 positive
cells in the tumor divided by the number of viable tumor cells and multiplied by 100) score as low
as 1, although the PFS was increased for patients with a CPS >10 (209). This is consistent with
emerging clinical data suggesting that systemic immune effects, rather than simple reactivation
of exhausted tumor-infiltrating T cells, is a major factor driving therapeutic responses (210).
Specifically, several murine studies have demonstrated that PD-L1 expression by conventional
dendritic cells (cDCs) is the major pathway driving PD-1-dependent exhaustion in T cells (211,
212). These studies demonstrate that understanding the cellular and molecular mechanisms
underpinning response to ICB is important for optimized selection of patients and therapeutic
combinations.
The next generation of ICB targets includes T-cell immunoglobulin and mucin domain
containing (TIM)-3. TIM-3 is co-expressed on exhausted T cells along with PD-1, and dual
blockade of PD-1 and TIM-3 demonstrates efficacy in preclinical models and early phase clinical
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trials (213). However, TIM-3 is also widely expressed by innate immune populations, including
constitutive expression by human and mouse conventional dendritic cells (cDC). We have
recently shown that TIM-3 blockade promotes the uptake of extracellular DNA by XCR1 + type I
cDCs (cDC1), leading to activation of the cGAS-STING pathway (200). TIM-3 blockade is thus
able to promote CD8+ T cell-dependent responses to paclitaxel (PTX) chemotherapy in models
of mammary carcinoma, despite the lack of TIM-3 expression by CD8+ T cells in these models
(139). Similarly, genetic loss of TIM-3 in cDCs promotes anti-tumor immunity in immunogenic
tumor models, whereas loss of TIM-3 in T cells does not alter tumor growth (214).
The data support TIM-3 expression by intratumoral cDCs as the primary target of
therapeutic antibodies, but it remains unclear how TIM-3 blockade indirectly promotes CD8 + T cell
effector function within tumors. We previously showed that intratumoral cDCs increase expression
of Cxcl9 and Cxcl10, and that the CXCR3 receptor is required for response to TIM-3 blockade
(139). Here we show that increased CXCL9 expression by XCR1 + cDC1s does not increase T
cell recruitment in mammary carcinomas, but rather promotes the spatial localization of cDC1 and
CD8+ T cells, thereby driving an interleukin (IL)-12-dependent therapeutic response. These
studies highlight that spatial organization of cDCs and T cells plays a critical role in the anti-tumor
response and delineate a pathway by which this can be targeted to improve T cell function.
Materials and Methods
Animal Studies
Animals were maintained in the University of South Florida (USF) Department of
Comparative Medicine barrier facility under protocols IS00004539, IS00008519, IS00002135, or
IS00005957 (see appendix A), and the respective Institutional Animal Care and Use Committee
approved all experiments. All mice were obtained from The Jackson laboratory, with the exception
of the Xcr1tm2(HBEGF/Venus)Ksho mice (194) which were obtained directly from Matthew Krummel at
UCSF. In order to generate bone marrow (BM) chimeric mice, recipient mice were irradiated with
2 doses of 5 Gy, 24 hours apart, followed by an intravenous BM transfer from donor animals.
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Tumors were implanted after 6 weeks of reconstitution, with implantation performed in 2-4 month
old female mice. Single-cell suspensions isolated from mammary tumors of MMTV-PyMT
transgenic mice were mixed in a 1:1 ratio with Matrigel (Corning), and 5 x 10 5 cells per 100 μL
were injected into the right 2/3 mammary gland. Treatment was initiated in a non-blinded fashion
when tumors reached an approximate average volume of 100 mm 3. Mice were dosed with
antibody αTIM-3 (clone RMT3-23), αCXCR3 (clone CXCR3-173), αIFNg (clone XMG1.2), αCD8b
(clone 53-5.8) or IgG2a (clone 2A3); BioXCell) alone or in combination with clinical grade
paclitaxel (PTX; Alvogen) as indicated in the respective s. Briefly, antibodies were administered
by intraperitoneal (i.p.) injection at 1.0 mg/mouse, with follow up doses of 0.5 mg per mouse every
5 days, concurrently with retro-orbital administration of 8-10 mg/kg PTX. For diptheria toxin (DT)
depletion models, DT was dosed beginning 2 days prior to the start of antibody treatment at a
concentration of 20 ng/g for the first dose, with follow up doses of 4 ng/g administered every other
day.
Generation of Bone Marrow-Derived DCs (BMDCs)
In order to generate BMDCs, mice were euthanized by CO 2 inhalation followed by cervical
dislocation. Tibias and femurs were removed and stored in PBS or media at 4˚C until processing.
To extract the bone marrow, muscle and tissue was removed from the bones using forceps and
surgical scissors. Once cleaned, one end of the bone was removed, leaving an opening from
which bone marrow could be extracted. For each bone, a set of nested Eppendorf tubes was
prepared as follows: 100 μL media or PBS was placed into a 1.5 mL Eppendorf tube. A 0.6 mL
Eppendorf tube was then placed inside the larger tube, and a 20- to 22-gauge needle was used
to puncture a hole in the base of the 0.6 mL tube. A bone was then placed into the smaller tube,
with the open side facing down. Tubes were centrifuged at 4000 x g for 1.5 min. After
centrifugation, the bone marrow cells should be pelleted in the liquid in the larger tube. The smaller
tube and the bones can then be discarded. Bone marrow was collected and resuspended in red
blood cell lysis buffer (155 mM NH4Cl + 12 mM NaHCO3 + 0.1 mM EDTA) before centrifugation
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at 400 x g for 5 minutes. Cells were then counted and plated at a density of 1.5 to 2 x 106 cells/mL
in complete media (RPMI + 10% FBS + 1% penicillin/streptomycin + non-essential amino acids
(from 100x stock) + sodium pyruvate (from 100x stock) + 55 μm beta-mercaptoethanol (added
fresh immediately prior to use), supplemented with specific concentrations of Flt3L and/or GMCSF, depending on the type of BMDC being generated. For GM-CSF BMDCs (which have a more
monocyte/macrophage-like phenotype (195)), media is supplemented with 10 µg/mL murine GMCSF, and cells are cultured for 7 days, with media added or changed at days 3 and 6 (to maintain
density of approximately 2 x 10 6 cells/mL. For Flt3L BMDC (which are a mix of cDC1 and cDC2),
media is supplemented with 100 ng/mL Flt3L-Fc (BioXCell), and cells are cultured for 8 days
without disturbance. For iCD103 BMDCs (which are >90% CD103 + cDC1 (196)), media is
supplemented with 200 ng/ml Flt3L-FC and 3.33 ng/mL GM-CSF, and cells are cultured for 1316 days. For these cells specifically, media is added on day 5 or 6 to minimize apoptosis. On day
9, the non-adherent portion of the culture is collected and diluted back to 1.5 to 2 x 10 6 cells/mL
in media supplemented with Flt3L-FC and GM-CSF as on day 1. In some cases, where indicated
in the text or figure legends, BMDCs were generated and resuspended at a concentration of 1 x
107 cells/mL in PBS, and 50 μL were injected directly into the tumor using a 27-guage needle.
Immunofluorescence (IF)
Following cardiac perfusion with PBS + 10 U/mL heparin, tissues were resected and
placed in 4% paraformaldehyde for 4-6 hours at 4˚C. Tissues were then transferred to 30%
sucrose and incubated on a shaker overnight at 4˚C. The tissue was then rinsed briefly in PBS
and embedded in O.C.T compound (Fisher Scientific), which was frozen on dry ice 4 μm sections
on charged slides were prepared by the Tissue Core Shared Resource at Moffitt Cancer Center.
Prepared slides were dried for 10 min at 50˚C, and excess O.C.T. compound was removed. Slides
were incubated in PBS + 0.3% Triton X 100 (Fisher Scientific) for 19 minutes at room temperature
(RT) to permeabilize tissue. Following 1 hour in horse serum blocking buffer containing 0.3%
Triton X 100, primary antibodies were diluted in the same, and applied for 3 hours at RT or
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overnight at 4˚C. Primary antibodies included chicken anti-GFP Tag (Thermo Fisher Scientific,
polyclonal, 1:1000 dilution), Alexa Fluor 647 conjugated anti-CD8a (BD Biosciences, clone 536.7, 1:250 dilution), anti-Ki67 (Cell Signaling Technology, clone D3B5, 1:400 dilution), anti-CXCL9
(Biolegend, clone MIG-2F5.5, 1:100 dilution). Following primary antibody incubation, slides were
re-blocked for 10 minutes at RT with horse serum blocking buffer + 0.3% Triton X 100. Secondary
antibodies were diluted in blocking buffer + 0.3% Triton X 100 and applied for 1 hour at RT.
Secondary antibodies included Alexa 555 conjugated Goat anti-Chicken IgY (Fisher Scientific,
1:500 dilution) and Alexa 488 conjugated Donkey anti-Rabbit IgG (Fisher Scientific, 1:500
dilution). For nuclear visualization, slides were incubated with 0.5 ug/mL Hoechst 33342 for 15
minutes at RT. Slides were washed with PBS and mounted using ProLong Gold anti-fade
mounting media (Invitrogen). Slides were scanned on a Zeiss Axio Imager Z1 at 20x magnification
using the tiled image option in Zen Pro (Zeiss).
Image Analysis
Tiled images were stitched using the stitching algorithm in Zen Pro, with shading adjusted
according to a reference image. Stitched CZI files were loaded into TissueStudio (Definiens).
Cells were identified by detection of Hoechst staining to determine the nuclear structure, with
subsequent identification of cytoplasmic staining. The area of each cell, mean intensity of each
channel within the cell, and location of the cell on the slide were reported. Cells with an area less
than 30 μm2 or greater than 200 μm 2 were excluded from further analysis. Threshold intensity
levels were set to exclude background fluorescence, and to determine mean intensity levels
sufficient to determine cDC1 (based on GFP expression) or CD8 + T cells (based on expression
of CD8). Using the (x,y) coordinates of each cell, the distance from each T cell to its nearest cDC1
was determined using in house MATLAB routines (Mathworks). The Kolmogorov-Smirnov test in
Prism Graphpad v 9 software was used to compare the distribution of distances from T cells to
the nearest cDC1. The data was plotted using the ggplot function in R, which plots the kernel
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density estimation of distributions such that when integrating over the curve the total probability
density sums to 1.
Flow Cytometry
Mice were cardiac perfused with PBS containing 10 U/mL heparin to remove peripheral
blood. Single cell suspensions were generated from minced tumors by digestion with 50 U/mL
DNAse I and 1 µg/mL Collagenase A (Roche) at 35˚C with agitation. Collagenase was omitted for
flow panels which included CXCR3 staining. Following digestion, cells were used immediately or
stored in 10% DMSO at -80˚C. Cells were plated at a density of 2 x 10 6/mL in PBS in a 96 well
plate for staining. Dead cells were stained by incubating a 1:1000 dilution of Zombie NIR
(Biolegend #423107), Live/Dead Aqua (Fisher Scientific, #L34965), or Zombie UV (Biolegend
#423107) fixable viability dyes in PBS for 30 minutes at 4˚C. To minimize non-specific staining,
the cells were then incubated with TruStain FcX Plus (anti-mouse CD16/32, Biolegend #156604)
at a concentration of 0.25 ug/mL diluted in FACS buffer (PBS + 1 mM ethylenediaminetetraacetic
acid (EDTA) + 1 mg/mL bovine serum albumin (BSA)). Immune populations were identified using
a previously described gating strategy (77) and the following antibodies: CD45 (clone 30-F11, BD
#564225), CD11c (clone N418, Biolegend #117334), F4/80 (clone BM8, Biolegend #123116),
MHCII (clone M5/114.15.2, BD #562564), CD11b (clone M1/70, BD #563168), CD103 (clone 2E7,
Biolegend #121426), Ly6G (clone 1A8, BD #563978), Ly6C (clone HK1.4, Biolegend #128026),
CD19 (clone 1D3, BD #564296), CD3ε (clone 17A2, BD #560527), CD8α (clone 53.6-7, BD
#564920), CD69 (clone H1.2F3, Biolegend #740220 or

#104506), CD44 (clone IM7, BD

#563970), CD4 (clone RM4-5, BD #563747), NK1.1 (clone PK136, Biolegend #108747), CXCR3
(clone CXCR3-173, Biolegend #126506), Ki67 (clone B56, BD #564071), FoxP3 (clone MF-14,
Biolegend #126403), IFN-γ (clone XMG1.2, Biolegend #505826), TNFα (clone MP6-XT22,
Biolegend #506306). Extracellular staining was performed by diluting antibodies 1:400 in FACS
buffer and incubating cells for 30 minutes at 4˚C. Cells were then fixed by incubation in BD Cytofix
for 30 minutes at 4˚C. To perform intracellular staining, cells were permeabilized using the BD
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Transcription Factor Buffer Kit (for panels that included Ki67 staining) or BD Cytoperm (all other
applications), both according to manufacturer’s directions. Data was collected with either an LSRII
or a FACSymphony flow cytometer, and all analysis was performed using FlowJo version 9 or 10
(FlowJo, LLC).
Statistical Analysis
Analysis of published scRNAseq data was performed using the panmyeloid platform
created by Cheng et al., 2021 (http://panmyeloid.cancer-pku.cn/; (64)). For growth curves
significance was determined via 2-way ANOVA with Tukey’s multiple comparisons test, with
significance shown for the final data point. A 2-way unpaired t-test or 2-way unpaired t-test with
Welch’s correction was used for comparison between groups with equal or unequal variance,
respectively. Comparisons between multiple groups were performed via 1-way ANOVA. Analyses
were performed using Prism 9 (GraphPad). Significance is shown as *p<0.05, **p <0.01,
***p<0.001 as described in each figure legend.
Results
CXCR3 Regulates T cell Effector Function but not Recruitment During Response to αTIM-3/PTX
Although response to TIM-3 blockade was CD8+ T cell-dependent (figure 3.1A), we
observed no increase in T cell infiltration by flow cytometry (figure 2.5A) or by quantification of
whole tissue sections by immunofluorescent microscopy (figure 3.1B). This was despite surface
expression of CXCR3 by over 60% of tumor-infiltrating CD8+ T cells (figure 3.1C-E). CXCR3 was
also found at lower levels on CD4 + T cells and a small population of cDC1s, with no change in
expression observed following treatment with αTIM-3/PTX (figure 3.1E). We next sought to
determine if the CXCR3-chemokine axis was regulating CD8 + T cell activation or effector function,
using an αCXCR3 blocking antibody that prevented response to αTIM-3/PTX (figure 3.1F) to
evaluate the role of this specific pathway in any observed changes. As in previous experiments,
we found no significant changes in CD8 + or CD4+ T cell infiltration as a result of TIM-3 blockade
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we found no significant changes in CD8 + or CD4+ T cell infiltration as a result of TIM-3 blockade

Figure 3.1: The CXCR3 axis does not promote T cell infiltration during TIM-3 blockade. (A)
Percent change in tumor volume from the start of PTX administration in mice treated with αTIM-3,
αIFN-γ and/or αCD8b as indicated. Merged data from 2 independent experiments; n = 13-16 mice
per group. (B) CD8+ T cells per mm2 of tumor, quantified from whole tumor immunofluorescent
images. Merged data from 4 independent experiments, n = 28 mice per group. (C) Representative
histograms showing CXCR3 expression by tumor CD4 + and CD8+ T cells, as well as cDC1. (D)
Mean fluorescence intensity (MFI) of surface CXCR3 on tumor T cells. Representative data from
1 of 3 independent experiments, n = 9 mice. (E) Mice bearing PyMT tumors were treated with PTX
and either aTIM-3 or the IgG2a control, without (left) or with (right) aCXCR3. Merged data from 2
independent replicates; n ≥ 14 mice per group. (F) Infiltration of CD8+ T cells (left) and CD4+ T
cells (right) in the tumors from (E). Shown as a percent of CD45 + cells. (G) Percentage of CD8+ T
cells expressing CD69, CD44, Ki67, or PD-1 after isolation from tumors treated with aTIM-3/PTX
versus IgG2a/PTX. Representative data from 1 of 2 independent experiments, n = 10 mice per
group. (G) Representative flow plots showing IFNγ expression by CD8+ T cells from PyMT tumors
following ex vivo stimulation with PMA and ionomycin, isolated 12 days post PTX. (I) Quantitation
of IFNγ expression by CD8+ T cells from G. (J) Quantitation of IFNγ expression by restimulated
CD8+ T cells isolated from mice treated with aTIM-3/PTX or IgG2a/PTX, ±AMG487. Merged data
from 2 independent experiments; n = 8 mice per group. Significance in A and E determined by
two-way ANOVA. Significance in F, I, J determined by unpaired t test. Shown as *p ≤ 0.05, **p ≤
0.01, n.s. = no significance.
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(figure 3.1G). Surprisingly though, blocking CXCR3 did not reduce T cell infiltration in any of the
groups, suggesting that this pathway is not critical for T cell recruitment into PyMT mammary
tumors. No change in infiltration was observed for either CD69 +CD103+ tissue-resident memory
CD8+ T cells or CD4+FoxP3+ regulatory T cells (figure 3.1H-I).
We therefore focused on expression of activation and effector molecules by CD8 + T cells.
There were no changes in the expression of CD69, CD44, PD-1, or Ki67 on either CD8+ or CD4+
T cells (figure 3.2A-B) within tumors following TIM-3 blockade. In contrast, following ex vivo

Figure 3.2: CXCR3 drives T cell effector function during TIM-3 blockade. (A-B) Percentage of
CD8+ (A) or CD4+ (B) T cells expressing CD69, CD44, Ki67, or PD-1 after isolation from tumors
treated with αTIM-3/PTX versus IgG2a/PTX. (C) Representative flow plots showing IFN-γ
expression by CD8+ T cells from PyMT tumors following ex vivo stimulation with PMA and
ionomycin, isolated 12 days post PTX. (D) Quantitation of IFN-γ expression by CD8+ T cells from
3.1F. (E) Quantitation of IFN-γ expression by restimulated CD8+ T cells isolated from mice treated
with αTIM-3/PTX or IgG2a/PTX, ±AMG487. (F) Quantitation of IFN-γ expression by CD4+ T cells
from 3.1F. Merged data from 2 independent experiments; n = 8 mice per group. Significance in A
and E determined by two-way ANOVA. Significance in F, I, J determined by unpaired t test. Shown
as *p ≤ 0.05, **p ≤ 0.01, n.s. = no significance.
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stimulation we observed a significant increase in the percentage of IFN-γ+CD8+ T cells in mice
treated with TIM-3/PTX expressed IFN-γ after ex vivo stimulation (figure 3.2C-D). This increase
was not observed when CXCR3 was inhibited, either with αCXCR3 (figure 3.2D) or the small
molecule CXCR3 antagonist (±)AMG-487 (figure 3.2E). Small increases in the percentage of IFNγ+CD4+ T cells in mice treated with TIM-3/PTX were also observed, but these were not significant
(figure 3.2F). Together, these results demonstrate that CXCL9 and CXCR3 play a critical role in
the ability of cDC1s to promote the effector function of CD8 + T cells but suggest that this occurs
through a mechanism other than T cell recruitment into tumors.
Intratumoral Injection of BMDCs Reduces Tumor Growth
cDC1s and CD8+ T cells are relatively infrequent within PyMT tumors. We therefore
hypothesized that CXCL9 expression by cDC1s was important for promoting an interaction
between the two populations, thereby allowing cDC1s to enhance T cell effector function. As a
preliminary means of assessing whether a decrease in the proximity of CD8+ T cells to cDC1
could support anti-tumor immunity, we decided to augment the number of DCs within the tumor

Figure 3.3: Intratumoral injection of bone marrow dendritic cells controls tumor growth.
(A) Number of recovered CD45.1+ cells at the indicated day post-injection. CD45.1+ bone marrow
derived dendritic cells (BMDCs) were intratumorally injected at day 0 (or a mock injection with
PBS was performed). Mice were euthanized and tumors harvested with cell presence assessed
by flow cytometry. (B) Percent tumor growth for mice treated with intratumoral injections of PBS
or wild type (WT) BMDCs every 5 days. N = 5 mice per group, 1 of 2 representative experiments
shown. (C) Percent tumor growth for mice treated with intratumoral injections of PBS, WT, or
Ccr7-/- BMDCs every 5 days. N ≥ 22 mice per group, merged from 2 experiments. *p<0.05,
**p<0.01; significance assessed by two-way ANOVA.
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microenvironment, thereby artificially decreasing the distance between a CD8 + T cell and its
nearest cDC1. To do so, we generated BMDCs from Ptprca mice, a C57BL/6J congenic strain
that expresses the CD45.1 allele (rather than CD45.2, as expressed in wild type C57BL/6J mice).
As CD45.1 and CD45.2 are distinguishable by flow cytometry using specific antibodies, this
allowed us to identify the CD45.1+ BMDCs following intratumoral injection. Using these BMDCs,
we performed intratumoral injections of 1 x 10 6 BMDCs suspended in sterile PBS and euthanized
the mice at the indicated day post injection (figure 3.3A), harvesting the tumor and running flow
cytometry in order to determine the timeframe during which injected exogenous BMDCs would
remain present in the tumor microenvironment. As the number of BMDCs identifiable post-tumor
harvest fell off between 4- and 6-days post-injection, we decided to inject BMDCs every 5 days
to examine whether altering the number of dendritic cells present in the tumor microenvironment
would affect tumor growth. As shown in figure 3.3B, intratumoral injection of BMDCs significantly
reduced the rate of tumor growth as compared to a PBS control injection. In order to rule out the
possibility that the injected BMDCs were augmenting anti-tumor immunity by trafficking to the
lymph node to present antigen, we generated BMDCs from Ccr7-/- mice, which lack expression of
the CCR7 receptor. As CCR7 is the primary receptor governing DC trafficking to the lymph node
(63), Ccr7-/- BMDCs should remain at the site of injection. Consistent with a local role for the
injected BMDCs, intratumoral injection of Ccr7-/- BMDCs reduced the rate of tumor growth to the
same extent as injection of WT Ptprca BMDCs (figure 3.3C).
αTIM-3 Promotes Co-Localization of cDC1s and CD8+ T Cells in a Cxcl9-Dependent Manner
To further evaluate the possibility that treatment with TIM-3/PTX drives alterations in
CD8+ T cell localization with respect to cDC1 within the tumor, we took advantage of specific
Venus expression by the cDC1 subset in the Xcr1-DTR mouse model (figure 3.4A), permitting us
to detect the cDC1 population by immunofluorescence using an anti-GFP antibody (figure 3.4B).
After staining for both Venus+ cDC1 and CD8+ T cell populations we set up a workflow to scan
whole tumor sections and determine the (x,y) coordinates of each cell (figure 3.4C). Cells were
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Figure 3.4: TIM-3 blockade promotes colocalization of cDC1 and CD8 + T cells. (A)
Representative histograms showing Venus expression by XCR1 + cDC1 in the spleen (left) and
tumor (right) of Xcr1-DTR mice. (B) Representative immunofluorescence microscopy images
showing XCR1+ cDC1 detected in the spleen (left) and tumor (right) of Xcr1-DTR mice, using a
polyclonal anti-GFP antibody to detect Venus expression. Scale bars: large image, 100 μm; inset,
50 μm. (C) Flow chart showing the procedure for determining the distance between CD8 + T cells
and the nearest cDC1. Following immunofluorescent staining for CD8 and GFP/Venus, tumors
are scanned and the (x,y) coordinates of each cell is attained using Definiens TissueStudio
analysis software. The (x,y) coordinates are then plotted in MATLAB and used to calculate the
distance between each CD8+ T cell and the nearest cDC1. Tumors for each treatment group are
then merged, and distances are plotted as a histogram. (D) Kernel density estimate of the
distribution of the total T cell population with respect to the distance between a CD8 + T cell and
its nearest cDC1. IgG2a/PTX treated tumors shown in red, αTIM-3/PTX treated tumors in blue.
(E) Representative image showing nucleus (blue), CD8 + T cells (green), and cDC1s (red). Scale
bar, 100 μm. (F-G) Quantification (F) and representative flow plots (G) of CXCL9 expression by
MHCII+CD11c+ splenic cDCs in Xcr1-DTR and Xcr1-DTR/Cxcl9-/- mice. (H) Kernel density
estimate of the distribution of CD8 + T cells in Xcr1-DTR/Cxcl9-/- mice.
mapped in 2D, and the distance between each CD8 + T cell and the nearest cDC1 was calculated,
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mapped in 2D, and the distance between each CD8 + T cell and the nearest cDC1 was calculated,
allowing the plotting of the cumulative distribution of distances between treatment groups. As
shown in figure 3.4D, adding TIM-3 to PTX chemotherapy induced a significant shift in the
distribution of CD8+ T cells towards cDC1s (Kolmogorov-Smirnov [K-S] D statistic = 0.153). This
required CXCL9, as increased proximity of CD8 + T cells to cDC1s was not observed after crossing
Xcr1-DTR with Cxcl9-deficient mice (figure 3.4E-H). Changes in cell distribution were not due to
alterations in the density of T cells or cDC1s within tumors (figure 3.1B, 3.5A). To determine if this
change was specific to cDC1s or represented a shift in CD8 + T cells towards stromal regions of
the tumor, we also assessed potential changes in the distribution of CD8 + T cells near CD68+
macrophages (figure 3.5 B-E). No apparent difference was observed between the IgG 2a/PTX and
αTIM-3/PTX groups, with the caveat that the density of macrophages was much greater than that
of cDC1 and almost all CD8+ T cells were within 100 µm.
Expression of the proliferation marker Ki67 identifies effector CD8 + T cells during response
to PD-1/L1 blockade (76, 215, 216) and works robustly for immunofluorescent staining (figure
3.5F). We therefore sought to use this marker to characterize the distribution of CD8+Ki67+ T cells
and determine if it was altered during TIM-3/PTX treatment. In IgG2a/PTX treated tumors,
CD8+Ki67+ and CD8+Ki67- T cells were equally distributed in relation to the nearest tumor cDC1
(figure 3.5G). However, in TIM-3/PTX treated tumors we observed that CD8 +Ki67+ T cells were
shifted towards cDC1 compared to CD8 +Ki67- T cells (K-S D statistic = 0.124). Combined with the
overall shift in T cell distribution following TIM-3 blockade (figure 3.4D), CD8 +Ki67+ T cells were
substantially closer to the nearest cDC1 (K-S D statistic = 0.239) in tumors treated with
combination therapy (figure 3.5H). This shift in the spatial localization of cells was not driven by
changes in the density of the CD8+Ki67+ T cells or the percentage of CD8 + T cells staining positive
for Ki67 (figure 3.5I-J). There was also no difference in CXCR3 expression between CD8 +Ki67-
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substantially stantially closer to the nearest cDC1 (K-S D statistic = 0.239) in tumors treated with

Figure 3.5: Additional data regarding the localization of CD8+ T cells in αTIM-3/PTX
treated tumors. (A) XCR1+ cDC1 per mm2 of tumor, quantified from the immunofluorescent (IF)
images in Figure 3.4. Merged data from 4 independent experiments, n = 28 mice per group. (B)
Representative IF showing Hoechst (blue), CD8a (green) and CD68 (red), Scale bar, 50 μm. (C)
Kernel density estimate of the distribution of CD8 + T cells with respect to the distance between
a CD8+ T cell and its nearest CD68+ macrophage. IgG2a/PTX treated tumors in red, αTIM-3 /PTX
treated tumors in blue. n = 9 tumors per group. Statistical difference between T cell localization
distributions determined by non-parametric Kolmogorov-Smirnov test, with the KolmogorovSmirnov D statistic shown. (D-E) CD8+ T cells (D) and CD68+ macrophages (E) per mm 2 in the
tumors examined in (C). (F) Representative IF stained tumor, showing Hoechst (blue), CD8α
(green), XCR1 (red), Ki67 (magenta). Arrow indicates a Ki67 +CD8+ T cell. Scale bars: 100 μm,
large image; 50 μm, inset. (G) Kernel density estimate of the distribution of Ki67 - (green) and
Ki67+ (blue) CD8+ T cells in IgG2a/PTX (left, n = 28) or αTIM-3/PTX (right, n = 34) treated tumors.
(H) Kernel density estimate of the distribution of the Ki67 +CD8+ T cell population within
IgG2a/PTX (red) versus αTIM-3/PTX treated tumors (blue). Statistical difference between T cell
localization distributions determined by non-parametric Kolmogorov-Smirnov test, with the
Kolmogorov-Smirnov D statistic shown. (I-J) Ki67+CD8+ T cell density (I) and Ki67 positivity as
a percent of CD8+ T cells (J), quantified from IF stained tumors assessed in (H). Merged data
from 4 independent experiments, n ≥ 28 mice per group. (K) Surface CXCR3 expression by
Ki67+ and Ki67- CD8+ T cells, as determined by flow cytometry. Data from 1 of 2 independent
experiments, n = 10 mice per group.
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or CD8+Ki67+ cells (figure 3.5K). Regardless, TIM-3 blockade reduced the distance between
XCR1+ cDC1 and CD8+ T cells, in particular the Ki67+ population.
cDC1 Production of IL-12 is Critical for Response to αTIM-3/PTX
We next sought to determine how cDC1 and CD8 + T cell interactions drove response to
αTIM-3 and PTX combination therapy. CXCR3 ligands are not known to regulate T cell activation,
suggesting either increased antigen presentation or exposure to stimulatory cytokines. To
interrogate the relevance of these functions, we again used the mixed BM chimera model system
to allow a normal immune response to develop following tumor implantation, followed by selective
depletion of cDC1 expressing the gene of interest (3.6A). As shown in figure 3.6B, B2m
expression by cDC1s was dispensable for response to αTIM-3/PTX, indicating that direct MHCIantigen presentation was not required for therapy. As antigen presentation by cDC1s is critical for
the initiation of de novo CD8+ T cell activation in the draining lymph nodes (61, 63, 69), these
results are also consistent with an intratumoral role for cDC1s following TIM-3 blockade.
cDC1s are a critical source of interleukin-12 (IL-12) within tumors. IL-12 is necessary for
CD8+ T cell-dependent responses in tumors (77, 78), and drives IFN-γ expression by activated
CD8+ T cells (figure 3.6C). This is true even after extended stimulation to induce T cell exhaustion
(figure 3.6D). Thus, we repeated the mixed BM chimera experiments, reconstituting irradiated
mice with 50% Il12b-/- BM (figure 3.6E). Here, DT administration to deplete the Il12-proficient Xcr1DTR+ cells completely abrogated response to TIM-3/PTX, without impacting tumor growth in the
presence of chemotherapy alone. The critical role of cDC1s in producing IL-12, as opposed to
presenting tumor antigen, was consistent with the minimal increase in the percentage of CD8+ T
cells within physical proximity of each cDC1 (<20 uM), as well as the limited number of CD8 + T
cells around a given cDC1 (figure 3.6F-G). In contrast, the percentage of CD8 + T cells within the
range of peak cytokine exposure (<100 uM) (217) substantially increased as a result of TIM3/PTX, as a greater percentage of cDC1s had >10 CD8+ T cells within this radius (figure 3.6H-I).
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Figure 3.6: cDC1 production of IL12 is required for response to αTIM-3/PTX. (A) Diagram
outlining the experimental approach for the in vivo experiments in (B) and (E). (B) Percent change
in tumor volume as compared to the start of PTX administration in mice reconstituted with 50%
Xcr1-DTR and 50% WT bone marrow (left) or B2m-/- bone marrow (right). n = 7-8 mice per group,
representative data from 2 independent experiments is shown. (C) Intracellular flow cytometric
staining for IFN-γ in splenic CD8+ T cells after a 48-hour stimulation with dilutions of plate-bound
αCD3/αCD28, in the presence of recombinant mouse IL-12 as indicated. Data from 1 of 2
independent experiments, error bars indicate technical triplicates. (D) Intracellular flow cytometric
staining for IFN-γ in splenic CD8+ T cells after a 48-hour stimulation with dilutions of plate-bound
αCD3/αCD28, in the presence of recombinant mouse IL-12 as indicated. Cells were prestimulated with plate-bound αCD3/αCD28 at the indicated concentrations followed by 1 week
culture in recombinant IL-2 before plating with recombinant IL-12. Data from 1 of 2 independent
experiments, error bars indicate technical triplicates. (E) Percent change in tumor volume in mice
reconstituted with 50% Xcr1-DTR and 50% WT (left) or Il12b-/- (right) bone marrow. n = 10 mice
per group, representative data from 2 independent experiments is shown. For B-C, *** indicates
p ≤ 0.001 by two-way ANOVA. (F) The number of T cells within 20 μm of a given cDC1. (G) The
percentage of T cells within 20 μm of a given cDC1. (H) The number of T cells within 100 μm of a
given cDC1. (I) The percentage of T cells within 100 μm of a given cDC1. Data in D-G quantified
from the images in Figure 3. Statistical difference between T cell localization distributions
determined by chi squared test, with the chi square value shown and *** indicating p ≤ 0.001.
Dual Expression of CXCL9 and IL12B is Rare Within Human Tumors
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Dual Expression of CXCL9 and IL12B is Rare Within Human Tumors
Using single cell RNA sequencing (scRNAseq), IL12B expression has been isolated to a
specific population of activated/mature CD83 +LAMP3+CCR7+ cDCs (39, 40). In most human
tumors, developmental trajectory analysis indicates that this mature LAMP3 + population largely
derives from the cDC1 lineage (64). Using these data, we sought to evaluate the extent to which
CXCL9 and IL12B were co-expressed within cDC populations. As shown in figure 3.7A,
expression of CXCL9, CXCL10, and IL12B were enriched in the LAMP3 + cDC3 subset in
carcinomas of the kidney, uterus, esophagus, and thyroid, as compared to the cDC1 or cDC2
population. CXCL9 and CXCL10 expression was also observed in the LAMP3 + cDC3 population
in breast cancer, but no transcripts for IL12B were detected in this data set. Despite expression
of CXCL9 and IL12B within the same population of cells, we observed limited overlap between

Figure 3.7: Expression of CXCL9 and IL12B within human tumor cDCs. (A) Expression of
CXCL9, CXCL10, and IL12B in cDC1, cDC2, and cDC3 subsets by scRNAseq in human kidney,
uterine, esophageal, thyroid, and breast cancers. (B-C) UMAP plot showing the cDC subsets from
human kidney carcinomas and expression of CXCL9 and IL12B. (D) Co-expression of CXCL9
and IL12B by individual cells in human kidney, uterine, esophageal, and thyroid cancers.
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gene expression within individual cells (figure 3.7B-C). Instead, IL12B expressing cells were
evenly distributed across CXCL9+ and CXCL9- cDC3s in all four types of carcinomas (figure 3.7D).
This suggests that CXCL9 production by cDCs may be insufficient to drive cDC and T cell
interactions in the absence of therapy, but that TIM-3 blockade and chemotherapy combinations
could potentially increase IL-12 exposure and enhance CD8 + T cell effector function in patients.
Discussion
Although the localization of cDC1s near CD8 + T cells is known to affect immune responses
in non-tumor immune contexts (71, 73, 218-220), the critical role of cDC1s in transporting tumor
antigen into draining lymph nodes and cross-presenting peptide-MHCI complexes to CD8+ T cells
has been the primary focus of therapies targeting these cells in cancer (59, 63, 69). While it has
been speculated that cDC1s may be important for presenting antigen to tumor infiltrating T cells,
our data suggest this is not the case in the context of PTX chemotherapy and TIM-3 blockade.
These findings underscore an important role for cDC1s in the tumor beyond presenting antigen
to CD8+ T cells and suggest that improved understanding of immune modulators could assist in
the decision-making process around trial design.
Using mixed BM chimeras, we found that expression of both Cxcl9 and Il12b by cDC1s
were critical for response to therapy. This is consistent with neutralization of IL-12 or inhibition of
CXCR3 preventing response to TIM-3/PTX (139) and limiting T cell effector function. However,
it was previously unclear how IL-12 and CXCR3 ligands were cooperating to regulate response
to TIM-3 blockade, as Il12b expression by myeloid cells was not impacted by therapy, while
increased expression of Cxcl9 and Cxcl10 by cDC1s did not alter T cell infiltration into tumors.
We describe here that TIM-3 blockade reduces the distance between CD8 + T cells and XCR1+
cDC1s, and that this shift is dependent upon Cxcl9. Notably, TIM-3 blockade had less impact on
the density of CD8+ T cells within the range of cell-to-cell contact with cDC1s, with the greater
difference noted in the density of cells within an area amenable to cytokine exposure. This
suggests that CXCL9 expression increases the proximity of CD8+ T cells to cDC1s producing IL66

12, thereby enhancing cytokine exposure and promoting effector function (221, 222). This also
offers a potential explanation for our observation that Ki67 +CD8+ T cells are located closer to
cDC1s than Ki67-CD8+ T cells during αTIM-3/PTX therapy, since IL-12 can promote T cell
proliferation (223). However, since we saw no increase in the density or frequency of Ki67 +CD8+
T cells, we cannot rule out other explanations such as preferential response to chemokines or
increased migratory capacity.
CXCL9 and IL-12 expression by cDC1s are also necessary for response to PD-1
immunotherapy, with increased IFN-γ production by T cells able to enhance chemokine and
cytokine expression by tumor cDCs (76, 78). It seems likely that CXCL9 will play a similar role in
promoting localization of CD8 + T cells and cDC1s during PD-1 treatment, but this remains to be
evaluated. Although we observed higher IFN-γ expression by CD8+ T cells during response to
TIM-3/PTX, and this was reversed upon inhibition of CXCR3 signaling, we find no change in
Il12b expression following αTIM-3 blockade in vivo (139). It is unclear how CXCL9 can promote
CD8+ T cell exposure to IL-12 and increase expression of IFN-γ by these cells, without a
corresponding response to IFN-γ by cDC1s. Potentially this is due to broad expression of the IFNγ receptor, with a higher number of cytokine consumers causing a reduction in the effective
diffusion distance of IFN-γ (217). In contrast, PyMT tumor cells do not express either subunit of
the IL-12 receptor, and high expression of Il12rb1 is restricted to T cells in this model (77). These
diffusion-consumption mechanics could result in cDC1 unidirectionally regulating T cell effector
function in tumor environments with poor IFN-γ expression. It is also possible that increased Il12b
expression by a small number of cDC1s was not detected when examining bulk gene expression
within the population; however, we also found no change in IL12p40 protein levels in cDC1s by
flow cytometry (139).
The critical role for CXCR3 in driving T cell infiltration into tumors has been extensively
described (224), with CXCR3 chemokine expression by tumor cells, macrophages, and cDC1s
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important in different systems (75, 203, 204). Given this, it is surprising that CXCR3 inhibition did
not impact T cell infiltration in PyMT tumors. This could reflect relatively poor T cell infiltration
overall in this tumor model, or alternate chemokines being important. Regardless, the data
indicates that boosting expression of CXCL9 and CXCL10 can prove efficacious across cancer
types. Beyond ICB with TIM-3 or PD-1, this includes therapies that target epigenetic regulators
(203, 225). It will be interesting to determine if improving chemokine expression by cDC1s can
prove synergistic with approaches that augment IL-12 expression, such as neutralizing IL-4 and
blocking the IL-10 receptor (40, 77). It will also be interesting to see if therapeutic efficacy will
depend upon the temporal and spatial dynamics of T cell and cDC1 interactions in the tumors, for
example, by bringing CD8+ T cells into proximity with cDC1 prior to administering stimulatory
therapies.
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Chapter 4: Results, Clinical Implications, and Future Work
Summary of Results
Based on our observations that TIM-3 was expressed by cDC1 in murine and human
mammary tumors, and that treatment with αTIM-3/PTX reduced the rate of tumor growth for a
murine model of breast cancer, we sought to understand the mechanism by which this occurred.
We found that treatment with αTIM-3/PTX increased Cxcl9 mRNA levels in tumors cDC1 isolated
during the middle of the therapeutic regimen. We further found that signaling through the CXCR3
axis, and specifically cDC1 production of CXCL9, was required for response to αTIM-3/PTX. While
αTIM-3/PTX promoted CD8+ T cell functionality, this was not through either increased antigen
presentation in the lymph node or through increased tumor infiltration by T cells.
We therefore sought to determine whether treatment with αTIM-3/PTX might drive
alterations in intratumoral organization of immune cells. Indeed, following αTIM-3/PTX treatment,
CD8+ T cells were located significantly closer to cDC1 than in IgG 2a/PTX treated tumors. This
phenotype was not observed in the absence of CXCL9, suggesting that increases in CXCL9
production following treatment with αTIM-3/PTX brings CD8+ T cells closer to intratumoral cDC1.
We further found that cDC1 production of IL-12, but not MHCI-mediated antigen presentation,
was required for response to αTIM-3/PTX, suggesting that the overall response to αTIM-3/PTX is
driven by CD8+ T cells being located closer to cDC1, and therefore interacting with cDC1produced IL-12, supporting CD8+ effector function (figure 4.1).
As TIM-3 blockade is being clinically evaluated in different tumor types and therapeutic
modalities, it is important to fully understand the mechanism of action in order to rationally design
therapeutic strategies incorporating αTIM-3. The work described herein provides insight into the
mechanism by which TIM-3 blockade functions when TIM-3 is primarily expressed by DCs, and
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not on the T cell compartment. Additionally, to our knowledge this work provides the first direct
evidence that treatment with a checkpoint blockade antibody can alter the localization of immune

Figure 4.1: Graphical representation of findings. We find that CD103+ cDC1 in mouse and
human breast tumors express TIM-3, and that combining TIM-3 blockade with paclitaxel
leads to initial levels of cell death, as well as CXCL9 release by cDC1. Treatment with TIM-3
blockade/paclitaxel also indirectly supports CD8 + T cell effector function. We find that cDC1specific CXCL9 is required for response to TIM-3 blockade and paclitaxel, and that treatment
drives increased spatial co-localization between CD8+ T cells and cDC1. The increased
spatial co-localization represents a likely mechanism for the observed increases in CD8 + T
cell effector function, as CD8 + T cells are therefore in closer proximity to cDC1 and cDC1produced IL12 (which is also required for response to therapy).
cells within the tumor beyond an overall increase in immune infiltration. It is possible that this
mechanism of action is also playing a role in the for other immunotherapeutic approaches,
particularly where other mechanisms, such as increased infiltration, have already been ruled out.
Investigation of the role of localization has been complicated by technical pitfalls, such as the
limited number of markers that can be evaluated at once using conventional microscopy
approaches, and the difficulty of evaluating large areas of interest in order to avoid biased
analysis. However, technical advances such as fluorescent whole slide scanning and multiplex
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immunofluorescence are becoming more widely available, and this methodology will certainly
improve our understanding of interactions between immune cells in the tumor microenvironment.
The Role of Intratumoral Localization in Anti-Tumor Responses
Our understanding of the organization of immune cell interactions within secondary
lymphoid organs is a relatively new area of research. However, the knowledge base has been
substantially expanded in recent decades as technologies such as two-photon microscopy have
become more accessible (226). In secondary lymphoid organs such as lymph nodes and the
spleen, as well as in non-tumor models of immunity, the organization of immune cells is tightly
controlled, with the presence of cells in specific regions allowing for interactions between immune
subsets and facilitating immune responses (72, 73). Understanding how cellular organization
facilitates interactions between CD8 + and CD4+ T cells and different antigen presenting subsets
within the lymph node has been a central area of research.
Within secondary lymphoid organs (i.e., spleens and lymph nodes), the organization of
immune cells is organized into regions of different cells, contributing to the function of the organs.
This organization is tightly controlled and allows for sequential engagement with antigens in a
way that facilitates the immune response. Using the lymph node as an example, as antigen (e.g.,
viral particles) enter the lymph node via lymphatics, subcapsular sinus (SCS) macrophages are
positioned nearby, allowing them to sample antigens and prevent further spreading throughout
the body (227). Innate lymphoid effector cells are located near SCS macrophages in the lymph
node, allowing for rapid innate immune responses to viruses, including rapid production of effector
molecules like IFN-γ (227). Following capture of antigens, SCS macrophages can also migrate
within the lymph node in order to engage with B cells, to initiate further anti-viral responses (228).
Both human and murine lymph nodes exhibit both B and T cell zones, within which these cells
are the most frequent cell type (219). Interestingly, B cells will also move within the B cell zone in
the lymph node following antigen engagement, moving towards the B/T cell zone border in order
to interact with T cells (229). Similarly, dendritic cells move within regions of the lymph node in
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order to help orchestrate immune responses. Under homeostatic conditions, dendritic cells in
secondary lymphoid organs are relatively immobile (229). However, upon activation and/or
maturation, dendritic cells became more mobile, and specifically moved toward B and T cell zones
within lymph nodes, presumably in order to facilitate interactions with B and T cells (229). The
movement of dendritic cells towards T cell zones within the lymph node and subsequent slow
movement near that zone has been shown to facilitate antigen sampling by CD4 + T cells, which
tend to move randomly within the T cell zone (230). Of note, individual DCs in the lymph node
can interact with up to 5,000 CD4 + T cells in an hour, largely driven by rapid CD4 + T cell motion
as they sample antigens (230). CD8+ T cells are similarly highly motile within lymph nodes, with
an individual DC potentially interacting with up to 500 CD8 + T cells per hour (231). Importantly,
these rapid and brief interactions support the need for DCs to be located near the T cell zone, as
the rapid motion of CD4+ T cells during antigen sampling may otherwise prevent interaction with
the DCs.
Both the cellular architecture in the lymph nodes and chemokine signals between cells
have been shown to contribute to the induction of adaptive immune responses (232). When
fibroblastic reticular cells, one of the stromal compartments of the lymph node, were deleted, the
subsequent loss of lymph node architecture and chemokine signaling resulted in reduced homing
of transferred CD8+ T cells and impaired adaptive immune responses to influenza infection (233).
Interestingly, when these cells were depleted after infection had been initiated, there was minimal
effect on the adaptive immune response (233), similar to our finding that treatment with FTY720
to prevent lymph node egress after the induction of anti-tumor immunity had little effect on
response to αTIM-3/PTX. In both cases, it is likely that although lymph node involvement is
required for initial induction of the immune response, local immune cells are largely able to support
the later stages of immunity. Of note, CXCR3 signaling has also been shown to play a critical role
in driving clustering of both effector and central memory CD8 + T cells with dendritic cells in the
lymph node (201, 234). In particular, one study showed that CXCL10 was produced largely by
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medullary macrophages, while CXCL9 was produced by SCS myeloid cells and CD11c + cells in
the lymph node (201), with dendritic cells included in the CD11c + subset. This highlights a
potential for differential signaling within the lymph node and raises the possibility that similar
signaling may explain some of the differences we observed in the requirement for CXCL9 vs the
lack of requirement for CXCL10 during response to αTIM-3/PTX.
Based on the literature, it is clear that in non-tumor models of immunity, the localization of
different immune subsets within lymphoid organs plays a role in both initiating and driving immune
responses. What has been less clear up to this point is whether similar dynamics were at play
during anti-tumor immune responses. A number of studies have highlighted the fact that, among
other factors, inclusion of CD8 + T cells within the tumor tends to be associated with improved
responses to therapy and with improved overall survival (235-239). Additionally, recent studies
have begun to examine the location of the infiltrating immune cells, and to classify tumors based
on the distribution of the immune infiltrate, generally highlighting whether immune cells are found
at the center or the margins of the tumor or are excluded altogether (240-242). However, these
studies are largely limited to examining levels of infiltration of an immune subset and/or to
examining where the immune cells are located with respect to the tumor as a whole, and are less
likely to examine where immune cells are located with respect to one another in the tumor. A
recent article examines the distribution of CD8 + T cells with respect to antigen presenting subsets
in triple negative breast cancer (240). However, rather than comparing differences in immune
distribution as a result of treatment, they examine whether the distribution of immune subsets with
respect to one another is different in tumors with different overall infiltration patterns. Our work,
outlined here in chapter 3, suggests that the distribution of CD8 + T cells with respect to a specific
antigen presenting cell, the cDC1 subset, is altered following treatment with αTIM-3/PTX.
Combined with the literature showing that immune distributions can predict patient responses
(240-242) and given that mice treated with αTIM-3/PTX show reductions in the rate of tumor
growth as compared to those treated with IgG2a/PTX, this suggests that alterations in the
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distribution of immune cells within the tumor may be necessary for and predictive of response to
certain immunotherapies.
An additional factor that may be of critical importance to the role of immune localization in
solid tumors is the presence or absence of tertiary lymphoid structures (TLS). TLS are lymphoid
aggregates that occur in tissues at the site of inflammation (243). Several studies have shown
that TLS presence has a positive prognostic value for a variety of solid tumor types (243),
including breast cancer (244-247). In non-tumor models, cDCs have been shown to play a key
role in the formation and maintenance of tertiary lymphoid structures (248, 249). Importantly, the
presence of LAMP-3+ cDCs in TLS in human non-small cell lung tumors correlates with increases
in cytotoxic CD8+ T cell function and a favorable TH1 CD4+ phenotype for cells within the TLS
(250), suggesting that mature cDCs may also play a key role in supporting the anti-tumor function
of cells within the TLS. Additionally, a study comparing the levels of chemokine gene expression
in TLS vs adjacent non-TLS tumor tissue from human lung tumors found that CXCL9, CXCL10,
and CXCL11 were all slightly increased in the TLS tissue (251). Based on our finding that CXCL9
production by cDC1 brings CD8 + T cells into proximity with cDC1 in mouse tumors, it is possible
that the CXCR3 ligands are playing similar roles in the context of human tumors, helping to drive
DC support of lymphocyte function within lung tumors. Although we do not observe TLS in our
murine tumor models, we have observed TLS in human breast tumors, and expression of TIM-3
within those TLS (chapter 2, figure 2.10A). This raises the possibility that treating breast cancer
with TIM-3 blockade could improve activity of TIM-3+ cells (likely DCs) within the TLS, helping to
drive anti-tumor immunity and improving responses for breast cancer patients.
Our work herein focuses on the role of cDC1 and CD8 + T cells, and interactions between
these two subsets of immune cells. However, other immune cells are also likely to play critical
roles within the tumor microenvironment, whether those roles are supportive or suppressive of
anti-tumor immunity. For instance, as was discussed briefly in Chapter 1, NK cell production of
different cytokines can drive cDC1 infiltration into tumors, and these cells are therefore potentially
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critical as an early step in driving anti-tumor immune responses that depend upon intratumoral
cDCs. Gene expression signatures associated with the presence of B cells are also associated
with response to immune checkpoint blockade (ICB) in melanoma tumors (252). The same study
showed that the presence of TLS containing B cells, T cells, and follicular DCs was predictive of
response to ICB (252), suggesting that interactions between different cell types within the tumor
are necessary for effective immune responses. In contrast, the presence of regulatory T cells
(Treg) in the TLS has been shown to inhibit immune responses (253, 254), consistent with the role
of these cells elsewhere in the tumor. In order to fully understand the role of immune cells within
the tumor microenvironment, and the importance of their spatial organization , it will be important
to conduct a detailed accounting of immune subsets within individual samples. This analysis is
becoming more feasible with advances in technology such as multiplex immunofluorescence
imaging. Along with combining multiplex IF with techniques such as laser capture microdissection
and sequencing, we will increasingly be able to perform in depth analyses to understand how
these interact within the tumor microenvironment and regulate the immune response against
tumors.
Integration of Tim-3 Blockade into Other Therapeutic Modalities
The altered distribution of CD8+ T cells with respect to cDC1 following treatment with αTIM3/PTX has implications for the design of therapeutic strategies. Our work suggests that treatment
with αTIM-3/PTX may be best suited for tumors in which CD8 + T cells are already present,
particularly when cDC1 infiltration is also observed. If TIM-3 blockade were to be added into a
therapeutic regimen then an ideal combination may involve agents that promotes immune
infiltration . As an example, Salmon et al. showed that combining BRAF inhibition combined with
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polyinosinic:polycytidilic acid (poly[I:C]) (to induce cDC1 accumulation and activation) increases
the number of tumor-infiltrating CD3+ T cells. Based upon our mixed bone marrow chimera
experiments demonstrating that IL-12 production by cDC1 is required for response to αTIM75

3/PTX, another option would be to use agents that enhance IL-12 expression, such as inhibition
of VEGF (129, 130) or blockade of IL-10 signaling (77, 136). Presumably increased CXCL9
expression following TIM-3 blockade would further enhance the exposure of T cells to the
expanded population of IL-12 producing cDC1s.
Given the use of PD-1 blockade and chemotherapy in triple negative breast cancer, the
most critical therapeutic question is whether the addition of αTIM-3 can boost the efficacy of the
approved combination. In a murine model of colon carcinoma, response to PD-1 blockade
requires crosstalk between IFN-γ and IL-12, produced by CD8+ T cells and cDC1, respectively
(78). One possibility is that adding TIM-3 blockade would enhance this crosstalk by further
increasing the cellular interactions between these two populations of cells. However, it has
recently been shown that cDC migration to the lymph nodes is necessary to sustain a population
of antigen-specific stem-like T cells (255, 256). Although we did not see a change in total lymph
node trafficking, we did observe a reduction in antigen delivery to the lymph node following TIM3 blockade. It is therefore possible that αTIM-3 could reduce the durability of the response to PD1 blockade and chemotherapy. This will need to be evaluated in future studies. It will also be
important to determine the reason for the reduced antigen delivery to the lymph nodes by cDC1s.
An improved understanding of this process should allow for the design of rational therapeutic
combinations that maximize the chances of eliciting responses in patients, thereby diminishing
the chances of failed clinical trials.
Future Directions
Understanding the mechanism of action of therapeutics is key to the design of rationally
implemented treatment strategies. Our work herein elucidates the mechanism by which αTIM-3
blockade controls tumor growth in a mouse model of breast cancer. It will be important to perform
similar studies in other tumor models to determine whether or not TIM-3 blockade functions via a
similar mechanism of action. For instance, in some tumors TIM-3 is expressed on highly activated
and/or exhausted T cells (257, 258). The application of TIM-3 blockade in these contexts may still
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be an effective therapy, but it is likely to function through different mechanisms, and this will need
to be taken into account during the design of combinatorial approaches. Expression of TIM-3 by
lymphocytes has also been shown to vary in endometriosis (259) and hepatitis B induced liver
failure (260), suggesting that comorbidities may need to be taken into account in the clinical
setting.
Additionally, our work to understand changes in immune cell organization during treatment
with αTIM-3/PTX focused on the relationship between CD8 + T cells and cDC1 or CD68 +
macrophages. However, the interactions between other cells in the tumor microenvironment (e.g.
NK cells and cDC1 (66, 79) or CD4+ T cells and cDC2 (82), among many others) may also play a
role in driving anti-tumor immune responses, albeit potentially in different therapeutic contexts.
Furthermore, the distribution of individual immune subsets with respect to different aspects of the
tumor architecture may help drive differences in immune functionality. Indeed, it has recently been
reported that differences in the distribution of lymphocytes within breast tumors is predictive of
response to anti-PD1 therapy (240), with tumors that exhibit lymphocyte infiltration into the core
of the tumor exhibiting better responses than those where lymphocytes remain at the tumor
margins (an ‘excluded’ phenotype).
Overall, our findings provide a mechanism of action for the response of mammary tumors
to αTIM-3/PTX. These findings may also be relevant in other diseases where TIM-3 is expressed
primarily by the cDC compartment. We also provide evidence that therapeutic intervention can
directly alter the organization of immune cells within the tumor microenvironment, and
demonstrate a local role for cDC1s in supporting the effector function of intratumoral CD8 + T cells.
It will be important to expand upon these studies to examine how interactions between immune
cells within the tumor microenvironment are altered by other therapies, and how the spatial
organization of immune cells drives anti-tumor immune responses to other forms of
immunotherapy.
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